



e-ISSN: 2791-9250

DAHUDER MEDICAL JOURNAL

Volume 4 · Issue 2 · April 2024

From diagnosis to management: navigating the complex terrain of granulomatous disease

The role of autoimmune thyroid disorders in patients with alopecia areata

A case of recurrent acute pancreatitis following ocrelizumab use



DAHUDER Medical Journal

<https://dergipark.org.tr/tr/pub/dahudermj>
e-ISSN:2791-9250

Aim and Scope

DAHUDER Medical Journal (DAHUDER MJ) is an international, independent, double-blind peer-reviewed, open access, and online publishing journal, which aims to publish papers on all the related areas of clinical medicine. Manuscripts must describe original data that has not been published previously nor submitted for publication elsewhere. Manuscripts that adhere to the DAHUDER MJ submission guidelines and are deemed appropriate for the scope of the journal are sent to two reviewers who are specialists in the field.

The members of the DAHUDER MJ Executive Editorial Board who discuss the suitability then consider the reviewers' comments on each submission. The final decision for all submitted manuscripts rests with the Editor-in-Chief.

Editorial Board of the DAHUDER Medical Journal complies with the criteria of the International Council of Medical Journal Editors (ICMJE), the World Association of Medical Editors (WAME), and the Committee on Publication Ethics (COPE).

The journal is published quarterly (January, April, July, and October).

No fee is required for publishing the manuscript.

All articles are detected for similarity.

Abstracting & Indexing

The journal is abstracted and indexed with the following: Google Scholar, ResearchGate, CrossRef, ResearchBib, Asos Index, ROAD, and OUCI.

Publisher

The Association of Internal Medicine Specialist (DAHUDER)

İtayçeşme Mah. Çam Sok.

DAP Royal Center D Blok Daire: 500

34843 Maltepe / İSTANBUL

<https://dergipark.org.tr/en/pub/dahudermj>

DAHUDER Medical Journal
hosted by Turkish Journal Park ACADEMIC,
is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License



EDITORIAL BOARD

EDITOR-IN-CHIEF

Nizameddin KOCA, MD,
Associate Professor,
University of Health Sciences,
Bursa Şehir Training & Research Hospital,
Department of Internal Medicine,
Bursa, Turkey

MANAGING EDITOR

Yasin Şahintürk, MD
Associate Professor
Antalya Training and Research Hospital
Department of Internal Medicine
Antalya, Turkey

PUBLICATION BOARD

Doğan Nasır Binici, MD
Professor
Erzurum Training and Research Hospital
Department of Internal Medicine
Antalya, Turkey

Teslime AYZA, MD,
Professor,
Department of Internal Medicine,
Rize Recep Tayyip Erdoğan University,
Rize, Turkey

Seyit Uyar, MD
Associate Professor
Antalya Training and Research Hospital
Department of Internal Medicine
Antalya, Turkey

Eşref Araç, MD
Associate Professor
University of Health Sciences
Diyarbakır Gazi Yaşargil Training & Research Hospital
Department of Internal Medicine
Diyarbarbakır, Turkey

Hasan Sözen, MD
Akdeniz Universtiy, Medical School
Department of Internal Medicine
Antalya, Turkey

Mustafa Çetin, MD
Çorum State Hospital
Department of Internal Medicine
Çorum, Turkey

INTERNATIONAL EDITORIAL BOARD MEMBERS

Erol Nargileci, MD
Columbus Regional Health, Southern Indiana Heart and Vascular Center
Department of Interventional Cardiology
Columbus, IN, USA

Mehmet AKKAYA, MD
Assistant Professor of Medicine Creighton University,
Cardiac Electrophysiologist
Omaha, NE, USA

Mahmut Fırat KAYNAK, MD
Department of Emergency Medicine
Al Emadi Hospital
Doha, Qatar

Table of Contents

Review

- From diagnosis to management: navigating the complex terrain of granulomatous disease** 35-53
Hakan Koç, Muhammet İlker Kaya, Nizameddin Koca

Original Articles

- The role of autoimmune thyroid disorders in patients with alopecia areata** 54-60
Hatice Nihal Şahin, Adnan Görgülü

Case Report

- A case of recurrent acute pancreatitis following ocrelizumab use** 61-63
Elif Işıklar, Berivan Akdoğan, Uygur Yavaş, İsmail Demir

From diagnosis to management: Navigating the complex terrain of granulomatous disease

Hakan Koç¹, Muhammet İlker Kaya¹, Nizameddin Koca¹

¹Department of Internal Medicine, University of Health Sciences, Bursa Faculty of Medicine, Bursa City Training and Research Hospital, Bursa, Turkey

ABSTRACT

In the realm of granulomatous diseases, the convergence of pathophysiology, epidemiology, and therapeutic strategies presents a labyrinth of complexity with far-reaching clinical implications. This review embarks on a scholarly expedition through the intricate landscape of granulomatous inflammation, dissecting the multifaceted presentations ranging from infectious etiologies to enigmatic autoimmune disorders. With a discerning eye on recent advancements and literature, we unravel the nuanced interactions between host defenses and granuloma formation, alongside the pivotal role of cytokines and mononuclear cells in orchestrating these responses. Beyond a mere academic exercise, our exploration delves into the clinical juxtaposition of common and esoteric causes, offering a panoramic view on diagnostic methodologies that straddle the traditional and the innovative. The management of granulomatous diseases, often a tightrope walk balancing efficacy and toxicity, is critically examined, shedding light on conventional and emerging therapies that promise to reshape the therapeutic landscape. By weaving together threads of current research, this review aspires to enhance the understanding of granulomatous diseases and catalyze future inquiries into their mysteries. In doing so, it stands as a beacon for clinicians.

Keywords: Granulomatous Disease, granuloma, cytokines, mononuclear cell, tuberculosis, brucellosis, sarcoidosis, Q fever, Wegener's.

Granulomas are chronic inflammatory limited lesions of mainly mononuclear cells that develop in response to antigenic stimuli and are formed due to an inflammatory reaction in body tissues. A granuloma is characterized by a central accumulation of mononuclear cells, mainly macrophages, with a surrounding framework of lymphocytes and fibroblasts. The lesions are distinct from nearby uninvolved tissue.

In the early stages of granuloma development, lesions

may appear as perforated histiocytes or lymphocyte clusters. Granulomas develop by stimulation of mononuclear cells by various cytokines. Activated macrophages are transformed to resemble epithelial cells (epithelioid cells), which characteristically have abundant, pale cytoplasm. Adjacent macrophages can fuse to form giant multinucleated cells.

The cells within the granuloma can secrete various proteins. For example, epithelioid cells from patients with sarcoidosis secrete lysozyme, collagenase, and angiotensin-converting enzyme (ACE).

Received: March 27, 2024; *Accepted:* April 22, 2024; *Published Online:* April 29, 2024

How to cite this article: Koç H, Kaya Mİ, Koca N. From diagnosis to management: navigating the complex terrain of granulomatous disease. DAHUDER MJ 2024,4(2):35-53. DOI: 10.56016/dahudermj.1459557

Address for correspondence: Hakan Koç, MD, Bursa Faculty of Medicine, Bursa City Training and Research Hospital, Bursa, Turkey
E-mail: koc_md@hotmail.com

Available at <http://dergipark.org.tr/en/pub/dahuderm>

Immune granulomas such as epithelioid cell granulomas and hypersensitivity granulomas are specific granulomas. The causative agent may not be seen in particular granulomas, but a microscopic diagnosis can be made based on the characteristics of the granulomatous inflammation.¹ Some causative agents may cause lesions of the three main types of inflammation (exudative, necrotic, and proliferative). Of these, only proliferative (granulomatous) lesions can be specific. Necrotic or exudative inflammations are not exact, regardless of the causative agent.

Immune granuloma formation is the result of a late hypersensitivity reaction involving T-lymphocytes. Alive agents that activate T-lymphocytes and other causes lead to the formation of immune granulomas. Most of the living agents that cause this picture are intracellular and slowly proliferating microorganisms.²

Non-immune granulomas (foreign body granulomas) are the granulomatous reaction that occurs in the presence of larger bodies or indigestible substances than a macrophage can phagocytize. The reacting bodies or substances do not stimulate the immune system because they do not contain antigens. They often cause a "foreign body reaction" by physical or chemical irritation. Objects that cause granulomatous reactions are categorized into two groups.¹

1-Endogenous: hair, keratin, cholesterol crystals, sodium urate (gout), dead bone tissue in osteomyelitis (sequesterite).

2-Exogenous: silicones (asbestos), berylliosis, sutures, parasite eggs, etc.

Granuloma Types

Caseating granuloma comprises epithelioid cells, giant cells, and lymphocytes and is characterized by central necrosis. Tuberculosis, fungal infection, and rheumatoid arthritis are examples of this group.

Non-caseating granuloma consists of epithelioid cells, giant cells, and lymphocytes. It does not contain central necrosis. Sarcoidosis, Beryllium, and Crohn's disease can be given as an example to this group.

Fibrin-rich granuloma shows a vacuole surrounded by fibrin in the center and epithelioid cells around it. It can be seen in Q fever, Hodgkin's disease, and giant cell arteritis.

Lipogranulomas show lipid vacuoles in the center and are associated with mineral fat intake.³

Granulomatous Involvement

-Skin Lesions (SLE, Psoriasis, Sarcoidosis, Cat

Scratch Disease)

-Lymphadenopathy (Lymphomas, Sarcoidosis, Tuberculosis)

-Eye and CNS Involvement (Sarcoidosis, Lymphoma, Whipple's Disease)

-Heart Involvement (Q Fever, Sarcoidosis)

-GI Involvement (Whipple's Disease, Crohn's Disease, Ulcerative Colitis, Tuberculosis, Typhoid Fever)

-Joint Involvement (SLE, Sarcoidosis, Brucella, Tuberculosis)

Causes of Granuloma

Infections

Tuberculosis, Brucella, Cat scratch disease, Lymphogranuloma Venerum, Paracoccidioidomycosis, Histoplasmosis, Aspergillosis, Cryptococcus neoformans, Leishmaniasis, Leprosy, Tularemia, CMV, EBV, Q fever

Autoimmune Diseases

Sarcoidosis, Ulcerative Colitis, Crohn's Disease, Primary Biliary Cirrhosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Temporal Arteritis, Wegener's Granulomatosis, Churg-Strauss Disease

Foreign body drugs and toxins

Allopurinol, methyldopa, sulfonamides, berylliosis, sutures, talc aluminum toxicity, Hypersensitive pneumonitis

Neoplastic

Lymphomas and carcinomas

Chronic Granulomatous Disease of Childhood

TUBERCULOSIS

Tuberculosis (TB) is a bacterial chronic infectious disease characterized by the formation of typical granulomas with caseation necrosis, which can affect almost every organ/tissue, especially the lungs. The causative agent of the disease is Mycobacterium tuberculosis, a genus of mycobacteria.^{4,5}

Mycobacterium tuberculosis is an intracellular bacillus in the Mycobacteria class, immobile, non-spore, 1-4 mm in size. Although it is obligately aerobic, it is a resistant bacillus that can survive without reproducing with very little oxygen in the environment. It does not stain Gram stain. They do not release their stain after treatment with acid and alcohol (Acid and alcohol-resistant bacilli).

Mycobacterium tuberculosis grows in a unique

enriched medium; colonies form in 3 - 8 weeks, and the growth temperature is 35 - 37 °C. They like oxygenated environments and are not resistant to heat and sunlight. They can remain viable in dry sputum for 6-8 months when protected from sunlight.

Various respiratory maneuvers have different potential to create particles (aerosols) in the air. Speaking produces 0-210, coughing 0-3,500, and sneezing 4,500-1,000,000,000 particles.⁶

Tuberculosis is transmitted by inhalation of particles (droplet nuclei) emitted by a tuberculosis patient, which are 1-5 microns in size and contain 1-3 viable bacilli. An untreated TB patient infects about 10-15 people each year. Infection and disease development after exposure to tuberculous bacilli The Contact - Infection - Disease cycle is shown in Figure 1.

In people not infected with TB bacilli and living in a high TB prevalence area, the likelihood of encountering TB bacilli, the duration of the encounter, and the susceptibility of the person are risk factors for becoming infected with TB bacilli.

Risk factors for the occurrence of active TB disease in people infected with TB bacilli are AIDS (170 times the risk), HIV infection (113 times the risk), Cancer, Diabetes Mellitus (3-16 times the risk), Drug addicts, Chronic renal failure, Low body weight (10% less than standard), Length of time after infection.

Tuberculosis Pathogenesis Stages

Phase I First Meeting (Figure 2).⁷

Phase II: Early Proliferation and Expansion (Figure 2).⁷

Phase III: Development of Cellular Immunity and Late Hypersensitivity (Figure 3).⁷

Stage IV: Lymphedema, Cavitation, Bacilli Proliferation and Endobronchial Invasion (Figure 4).⁷

Progressive Primary Tuberculosis (Pediatric Tuberculosis)

Following primary infection, 5% of infected patients develop progressive primary disease. In communities where TB is prevalent, primary TB is more common in childhood and the newborn period.⁸ It is more common in immunocompromised patients, such as those with advanced HIV (Figure 5).¹⁰

Post-primary Tuberculosis (Adult-type Tuberculosis)

It usually occurs weeks or years after the primary infection with activation of latent infection in the upper zones of the lungs.⁹

Post-primary tuberculosis is primarily an adult disease (Figure 5).

Pulmonary tuberculosis

Is a disease picture involving the lung parenchyma. Tuberculosis disease affects the lungs in 70-80% of




Figure 1. Contact - Infection - Disease cycle




Figure 2. Figure 3. Pathogenesis of Tuberculosis.⁷

cases. Pleural effusion or mediastinal lymph node enlargement without involvement of the parenchyma is considered extrapulmonary.

Extrapulmonary tuberculosis

Is defined as patients with ARB in samples taken from organs other than the lung parenchyma or with histologic and clinical findings compatible with tuberculosis. Extrapulmonary Tuberculosis involvement sites include the pleura, central nervous system, lymphatic system, genitourinary system, bone, and joints.¹¹

Clinical Presentation

Tuberculosis patients may present with respiratory symptoms such as cough, sputum production, hemoptysis, chest pain, back and side pain, shortness of breath, hoarseness and/or systemic symptoms such as fever (intermittent), night sweats, loss of appetite, weight loss, weakness, fatigue, and organ-specific symptoms (LAP, hematuria, joint swelling, etc.).

Patients with cough lasting more than three weeks and whose pulmonary findings do not improve with antibiotic treatment should be investigated for tuberculosis. There is no respiratory system physical examination finding specific to tuberculosis. If the




Figure 3. Pathogenesis of Tuberculosis.⁷




Figure 4. Pathogenesis of Tuberculosis.⁷

consolidation area is located close to the chest wall, rales may be heard in the background of bronchial sound. Amphoric sounds may be heard in patients with cavitory lesions.

Diagnosis

Bacteriologic diagnosis is essential in tuberculosis. Specimens that may be examined (Sputum, induced sputum, fasting gastric juice, bronchoscopic aspiration fluid, CSF, pleural fluid, urine, joint fluid, biopsy material, etc.).

Microscopy

An ARB examination with Ziehl-Neelsen staining in the morning sputum was collected on three consecutive days.

Culture

Inoculation of the microscopically examined material on Lowenstein-Jensen solid and/or automated liquid media. Production of tubercle bacilli in culture is the gold standard diagnostic method.¹²

Drug susceptibility test

Investigation of the susceptibility of the cultures to the antituberculosis drugs used in treatment.

The presence of ARB on direct examination of sputum or other specimens does not confirm the diagnosis. Culture is more sensitive than microscopy (sensitivity 80-85%, specificity 98%).

Tuberculin Skin Test (TST) and Interferon Gamma Release Tests are not recommended to diagnose active




Figure 5. Tuberculous infection and disease development.¹⁰

TB in adults. These tests are positive in both latent TB infection and TB disease. They are positive as a result of late-type hypersensitivity due to TB bacilli.

TST shows whether a person is infected with TB bacilli; it does not give information about the disease. It may indirectly help in the diagnosis of the disease.¹³ Criteria for evaluation of TCT reaction in Türkiye are as below.¹⁴

Patients Vaccinated with Bacille Calmette Guerin (BCG):

- 0-5 mm is considered negative.
- 6-14 mm is attributed to BCG.
- 15 mm and above are considered positive and considered infection.

Patients without BCG:

- 0-5 mm is considered negative.
- 6-9 mm is considered suspicious. The test is repeated after one week; if 6-9 mm is found again, it is considered negative.
- 10 mm and above is considered positive.
- In immunocompromised individuals, 5 mm or more is considered positive

Interferon-gamma (IFN- γ) regulates the cellular immune response to M. tuberculosis infection. IFN- γ release assays are in vitro tests that measure the cellular immune response to M. tuberculosis antigens. There are currently two commercial IFN- γ release assays. The ELISA-based assay is the QuantiFERON assay, which measures the level of IFN- γ released from T-cells, and the ELISPOT-based assay is the T-SPOT assay, which measures the number of T-cells producing IFN- γ .¹⁰

Nucleic acid amplification tests (NAAT) are another diagnostic method used to diagnose tuberculosis.¹⁵ It is used in the diagnosis of tuberculosis, species identification in Mycobacteria, and detection of drug resistance.¹⁶

In histopathologic examination, granulomatous inflammation, especially caseification necrosis, in biopsy material taken from any tissue is a characteristic finding for tuberculosis.¹⁷

Chest X-ray

No radiologic finding is specific to Pulmonary Tuberculosis.¹⁸ Imaging methods are not definitive diagnostic tests for TB. They are diagnostic aids. The main radiologic findings on chest radiography

in post-primary tuberculosis are local exudative lesions, cavitation, bronchogenic extension, acute tuberculous pneumonia, local fibro calcified lesions, miliary tuberculosis, and tuberculoma. Cavities are found in approximately 40% of cases, and 95% of adult pulmonary tuberculosis is located in the apical, posterior segments of the upper or superior segments of the lower lobes.¹⁹

Thorax CT and HRCT (High-Resolution Computed Tomography) provide superiority in the early diagnosis of parenchymal diseases, early diagnosis of Miliary Tuberculosis, detection of Endobronchial lesions, detection of small cavities and parenchymal lesions covered by Pleural fluid.²⁰

Treatment

Tuberculosis is a group-A notifiable infectious disease. It is reported to the Health Directorate within 24 hours of diagnosis.²¹ First-generation drugs used to treat tuberculosis are Isoniazid, Ethambutol, Streptomycin, Pyrazinamide, and Rifampicin.²²

In the Initial Phase (Initial Period), the treatment goal is to rapidly reduce bacilli with Early Bactericidal Activity and provide a Preventive Effect on Resistance Development.

In the Maintenance Phase, the treatment goal is to ensure sterilization by destroying all semi-dormant bacilli.

In the treatment of tuberculosis in new cases, a two-month 4-pack combination (Isoniazid + Rifampicin + Pyrazinamide + Ethambutol / Streptomycin) is used in the initial phase, and a month 2-pack combination (Isoniazid + Rifampicin) is used in the maintenance phase.

In case of relapse, in addition to the previous treatments, two months of 5-pack combination (Isoniazid + Rifampicin + Pyrazinamide + Ethambutol + Streptomycin) or one month of 4-pack combination treatment (Isoniazid + Rifampicin + Pyrazinamide + Ethambutol), and five months of 3-pack treatment (Isoniazid + Rifampicin + Ethambutol) in the maintenance phase.

Directly Supervised Treatment (DST) is mandatory in the hospital. The supervisor who administers the treatment monitors the patient to ensure that all TB medication is taken and makes sure that the patient takes the medication by standing over the patient while the patient takes it. When the patient has taken the medication, the patient and the supervisor sign the DST form.

DST in a tuberculosis dispensary

The dispensary has the lead or coordinating role in implementing DST during outpatient treatment. The TB dispensary physician must make the supervision plan for the patient, determine the person who will implement supervision, and determine where and when the medication will be administered.²³

BRUCELLOSIS

Brucellosis is a bacterial zoonosis transmitted directly and indirectly from infected animals, especially domestic ruminants and swine, to humans.²⁴ *Brucella* strains cause human brucellosis. All *Brucella* bacteria are small, gram-negative, non-capsulated, non-spore, comma, or coccobacilli. These organisms are sensitive to sunlight, ionizing radiation, and moderate heat; they can be killed by boiling and pasteurization but resist freezing and desiccation. *Brucella melitensis* is transmitted by sheep, goats, and camels; *B. abortus* is transmitted mainly by cattle and bulls; *B. suis* is usually transmitted by pigs; and *B. canis* is transmitted by dogs.²⁵

Brucellosis Clinical Presentation

Brucellosis invariably causes fever with profuse sweating, especially at night.²⁶ The fever is accompanied by muscle and joint pain in half or even all patients with brucellosis. In addition to the usual fever and sweating, patients become increasingly apathetic and fatigued, with anorexia, weight loss, non-specific muscle pain, headache, and lethargy. Musculoskeletal pain and physical examination findings in the periphery and spine (in 40% of cases) are the most common symptoms.²⁷ Osteomyelitis is more common in the lumbar and lower thoracic vertebrae than in the cervical and upper thoracic vertebrae. The joints affected by septic arthritis are the knee, hip, sacroiliac, shoulder, and sternoclavicular joints. Involvement may be monoarthritis or polyarthritis. Osteomyelitis may accompany septic arthritis.

One-fourth of patients have pneumonia, empyema, intrathoracic adenopathy, and lung abscess on chest X-ray, but dry cough with little change. One-fourth of patients have hepatosplenomegaly, and 10-20% have marked lymphadenopathy. Up to 10% of men develop acute epididymo-orchitis, which must be differentiated from mumps and surgical conditions such as torsion. Prostatitis, inflammation of the seminal vesicles, salpingitis, and pyelonephritis also develop. Although teratogenicity has not been

established, and abortion is less common in humans than in animals, there is a risk of fetal loss in infected pregnant women.²⁸ Neurotuberculosis, or lymphocytic meningoencephalitis, mimics non-infectious causes and can lead to intracerebral abscess, disorders of various cranial nerves, and mycotic aneurysms, is common.²⁹ Less than 1% of patients develop endocarditis, often involving the aortic valve (natural or artificial). Metastatic abscesses and inflammation develop in any part of the body. Remarkably, the female breasts and thyroid glands are frequently affected. Non-specific maculopapular tingling and other cutaneous manifestations are rare; if they occur, they are rarely reported by the patient.

Diagnosis

Isolation of bacteria from blood, CSF, bone marrow, joint fluid tissue aspirates, and biopsy material is diagnostic.³⁰ In tissue biopsy specimens such as lymph nodes or liver, non-classified granulomas without acid/alcohol-resistant bacilli are found. The serologic examination is often the only positive laboratory finding in diagnosing brucellosis. IgM antibodies are formed early in acute infection, followed by IgG and IgA. In endemic areas or in case of occupational contact, an agglutination titer of 1/320 - 1/640 or more is diagnostic. In non-endemic areas, a titer of 1/160 and higher is considered significant. Repeat tests after 2-4 weeks may show an increase in titer. In most centers, the standard agglutination test (SAT) is the primary test used for serological diagnosis. Although some investigators trust the Rose-Bengal test, it is not fully validated for human diagnosis. The anti-*Brucella* IgM dipstick test is used to diagnose acute infection, but its sensitivity is low in infections with symptoms lasting several months. In endemic areas, >90% of patients with acute bacteremia have SAT titers of at least 1/320.

Treatment

The gold standard treatment of brucellosis in adults is the combination of intramuscular streptomycin (0.75 to 1 g per day for 14-21 days) with doxycycline (100 mg twice daily for six weeks). Clinical and observational studies have shown that the recurrence rate in patients with this treatment is 5-10%. An alternative to this treatment (recommended by the World Health Organization) is the use of rifampin (600-900 mg/day) plus doxycycline (100 mg twice daily) for six weeks.³¹ Instead of streptomycin, other aminoglycosides such as netilmicin or gentamicin 5-6

mg/kg/day for at least two weeks (shorter courses have a high failure rate in adults). High doses of ofloxacin (400 mg twice daily) or ciprofloxacin (500 mg twice daily) combined with rifampin for six weeks may be an alternative to other 6-week treatment regimens in adults. Significant neurologic disorders due to *Brucella* require prolonged treatment (i.e., 3-6 months) with ceftriaxone added to the standard treatment regimen. *Brucella* endocarditis is treated with at least three drugs (an aminoglycoside, a tetracycline, and rifampin). Most experts add ceftriaxone and/or fluoroquinolone to reduce the need for valve replacement. Treatment is usually given for at least six months.

TULAREMIA

Tularemia is a zoonosis caused by *Francisella Tularensis*.³² It can develop in any age, gender, and race, and almost everyone is susceptible to the disease. Tularemia is usually a disease of wild animals and survives in contaminated environments, ectoparasites, and carrier animals. Human infection is accidental and usually occurs through interaction with blood-sucking insecticides, contact with wild or domestic animals, ingesting contaminated water and food, or inhaling infected aerosols. Tularemia is characterized by pyogranulomatous pathology with mononuclear cell infiltration. Histopathologic findings are very similar to tuberculosis. However, it develops much faster in tularemia. As a facultative intracellular bacterium, *F. tularensis* can survive for long periods of time in both phagocytic and nonphagocytic host cells. In the acute phase of infection, focal areas of necrosis are present in the primary affected organs (skin, lymph nodes, liver, and spleen). They are initially surrounded by polymorphonuclear loci (PNL). Granulomas with epithelioid cells, lymphocytes, and multinucleated giant cells develop around the necrosis area. These areas may resemble caseating necrosis but later coalesce into an abscess.

Diagnosis

The diagnosis of tularemia is often made by agglutination testing. Microagglutination and tube agglutination tests are the most commonly used tests for detecting *F. tularensis* antibodies.³² A standard tube agglutination titer of 1/160 and above is considered positive. A four-fold increase in the titer in serum samples taken 2-3 weeks later is diagnostic.

Treatment

Streptomycin, gentamicin, and quinolones can be

used in treatment [33].

CAT SCRATCH DISEASE (CSD)

CSD is a self-limiting disease characterized by regional lymphadenopathy lasting weeks to months. *Bartonella Henselae* is the main causative gram-negative microorganism [34]. Rarely, patients with CSD develop disseminated *B. Henselae* infection.

Risk factor: Cat scratching or biting.

Clinical signs initially - the primary inoculation lesion - are papules, vesicles, or nodules 0.5-1 cm in size at the site of inoculation with *B. henselae* and persist for approximately 1-3 weeks. Adenopathy typically develops 2-3 weeks later (between 3-50 days) after scratching or biting. Unilateral solitary or regional lymphadenopathy is seen in more than 90% of cases. Their location coincides with areas of lymphatic drainage. The lymph nodes are painful, firm, mobile, and suppurative, with approximately 10% rarely erythematous. Nonsuppurative systemic symptoms such as fever, anorexia, headache, myalgia, malaise, and abdominal pain are variably present at this time. Lymphadenopathy usually resolves within three months. Histologic examination of lymph nodes in the early phase of CSD reveals follicular hyperplasia and arteriolar proliferation. Within weeks, cortical granulomas, multinucleated giant cells, neutrophilic infiltrates, and micro abscesses with a tendency to coalesce (satellite microabscesses) are observed. The granulomas are surrounded by histiocytes and peripherally by lymphocytes. Typical clinical findings and a history of cat contact suspect the diagnosis of CSD.

Diagnosis

In most cases, a lymph node biopsy or aspiration is necessary to exclude other diseases and to make a diagnosis. In such cases, polymerase chain reaction (PCR) examination of tissue samples is usually preferred. Lymph node tissue cultures are rarely positive³⁵

Treatment

Most typical cases of CSD resolve without treatment. Some experts recommend treatment with azithromycin to accelerate the resolution of lymphadenopathy [36]. Antimicrobial therapy for CSD is universally recommended in immunosuppressed patients.

LYMPHOGRANULOMA VENERIUM (LGV)

It is a sexually transmitted disease caused by L1, L2, and L3 serovars of *Chlamydia Trachomatis*. Classically, acute LGV is characterized by a transient primary genital lesion followed by multilocular suppurative regional lymphadenopathy.³⁷ The primary genital lesion appears within three days to 3 weeks after exposure. It is a small, painless, vesicular, or indurated ulcer or papular lesion located on the penis in men and labia or posterior vagina in women. Acute LGV is almost always associated with systemic symptoms such as fever and leukocytosis, but systemic complications such as meningoencephalitis are rare. Nocturnal complications that develop over years if left untreated include genital elephantiasis due to lymphatic involvement, adhesions, and fistulas of the penis, urethra, and rectum.

Diagnosis

There are four different laboratory methods to confirm *C. Trachomatis* infection: direct microscopic examination of tissue samples to visualize typical intracytoplasmic inclusions or elementary bodies; isolation of the organism in cell cultures; immunological detection of chlamydia antigens or chlamydia genes by NAAT; detection of antibodies in serum or local secretions.³⁸

Treatment

In LGV, doxycycline (2x100 mg PO) or erythromycin base (4x500 mg PO) is recommended for at least three weeks.³⁸

Q FEVER

Q fever is a zoonotic infection caused by *Coxiella burnetii*. These organisms have a spore form that allows them to survive in harsh environmental conditions. The primary source of human infections is infected cattle and sheep. *C. burnetii* can also be transmitted to humans by cats, rabbits, pigeons, and dogs.³⁹ Chronic Q fever, almost always meaning endocarditis, is usually seen in patients with previous heart valve disease, immunosuppression, or chronic renal failure. Valvular vegetation is detected in only 12% of patients on transthoracic echography but a higher percentage on transesophageal echography. Vegetation in chronic Q fever endocarditis differs from that in bacterial endocarditis, where it appears as an endothelialized nodule on the valve. A high level of suspicion is required for correct diagnosis. Q fever should always be suspected in patients with culture-negative endocarditis.⁴⁰

HISTOPLASMOSIS

Histoplasma capsulatum, a thermally dimorphic fungus, is the etiologic agent of histoplasmosis. When soil containing the organism is tilled, the microconidia become airborne and are transmitted to nearby people. Activities that lead to contact with high concentrations of the fungus include caving, excavation, cleaning chicken coops, demolition and renovation of old buildings, and felling of mature trees. Infection occurs after inhalation of microconidia.⁴¹ Once microconidia reach the alveolar spaces, they are rapidly recognized and phagocytosed by alveolar macrophages. At this point, the microconidia transform into budding yeasts; this transformation is essential for the pathogenesis of histoplasmosis and depends on the presence of calcium and iron in the phagocyte. Yeasts can grow and multiply within resting macrophages. In the immunocompetent host, macrophages, lymphocytes, and epithelial cells organize and form granulomas containing the organism. These granulomas typically show fibrotic changes and calcify. Calcified mediastinal lymph nodes and hepatosplenic calcifications are often found in healthy individuals living in endemic areas. The gold standard diagnostic test for histoplasmosis is fungal culture.

Treatment

Liposomal Amphotericin B more than two weeks in case of disseminated disease, followed by itraconazole 3x 200 mg 3 days, followed by 2x200 mg \geq 12 months. In mild cases, itraconazole 3x200 mg 3 days, followed by 2x200 mg \geq 12 months.

Prophylaxis: CD4 T lymphocyte count $<$ 150 cells/mm³ + living in an endemic area indicates prophylaxis and medical treatment can be adjusted as Itraconazole 200 mg/day.⁴²

SARCOIDOSIS

Sarcoidosis is a systemic granulomatous disease of unknown cause. The most common populations are Scandinavians and African Americans.⁴³ The estimated annual incidence of sarcoidosis in Turkey is 4/100,000.⁴⁴ The most common age of onset is 20-40 years, the second most common age is over 50 years, and it is more common in the female gender. It is more common in non-smokers (approximately 75% of cases).⁴⁵

In sarcoidosis, a cellular immune response is triggered by antigen. When the cytokines released are analyzed, it is thought to be a T-helper 1 (Th1) mediated immune response. In sarcoidosis, CD4+

Th1 cells and macrophages gather in areas where inflammation is prominent, especially in the lungs. Granulomas are formed by the cytokines secreted by these cells.⁴⁶

The typical histopathologic lesion of sarcoidosis is dense epithelioid cell granulomas without caseating necrosis. Granulomas contain epithelioid cells, giant cells (asteroid bodies and Schumann bodies), and lymphocytes. Granulomas may disappear or progress to fibrosis.⁴⁷

The most common organ involved in sarcoidosis is the lungs. While many patients with pulmonary sarcoidosis are asymptomatic and diagnosed incidentally with chest radiography, some patients may present with non-specific complaints such as exertional dyspnea, cough, fatigue, and chest pain.^{48,49}

Physical examination findings in pulmonary sarcoidosis are not very specific. Despite radiologic prevalence, rales can be heard in up to 20% of patients. Development of clubbing is rare. Cor pulmonale may develop in very advanced cases.⁵⁰

Radiologic staging in sarcoidosis is performed according to chest radiography:⁵¹

Stage 0: Normal chest radiography

Stage 1: Bilateral hilar lymphadenopathy

Stage 2: Parenchymal infiltration with bilateral hilar lymphadenopathy

Stage 3: Parenchymal infiltration only

Stage 4: Fibrosis

Extra-thoracic Involvement

Approximately one-third of patients have palpable peripheral lymph nodes. Cervical, axillary, epitrochlear, and inguinal lymph nodes are most commonly involved.⁵² Skin involvement occurs in one-third of patients and is the most common extra-thoracic manifestation of sarcoidosis.⁵³ Erythema nodosum is the most common non-specific skin lesion. It is typically painful, erythematous, and predominantly found on the anterior aspect of the lower extremities.⁵⁴

Ocular sarcoidosis is the second most common extra-thoracic manifestation. Reported ocular involvement ranges from 10% to 25% and is more common in blacks and women.^{53,55,56} Any part of the eye can be affected; uveitis is the most common form of involvement.

Joint pain occurs in 25-39% of patients with sarcoidosis, while deforming arthritis is rare [57]. The most commonly involved joints are the knees, ankles,

elbows, wrists, and small joints of the hands and feet.

Liver involvement is quite common (30% in the antemortem series and up to 80% in the postmortem series).⁵⁸ Most patients are asymptomatic, with non-specific abdominal pain, nausea, and fatigue being the most common symptoms.^{59,60} The prognosis is good with spontaneous regression and rapid response to corticosteroids.^{59,60}

Involvement of the nervous system in patients with sarcoidosis ranges from 3% to 10%.^{53,58} Systemic manifestations of sarcoidosis are also observed in more than 90% of cases of neurosarcoidosis, especially in the lungs and intrathoracic lymph nodes. Any part of the nervous system can be affected, and multiple involvement can occur in a single patient. The most commonly involved areas are the cranial nerves, meninges, and brain parenchyma.⁶¹

The classical renal involvement of sarcoidosis is granulomatous interstitial nephritis, which has been observed in 20% of postmortem studies.^{62,63}

Cardiac Involvement

The reported cardiac prevalence in sarcoidosis ranges from 1% to 23%.⁵⁸ Differences in the methods and criteria used to detect and diagnose cardiac sarcoidosis are probably responsible for this wide range.⁵⁴ Cardiac sarcoidosis involvement may occur in isolation without the involvement of other organs. The significant pathology here is granulomatous inflammation of the myocardium, leading to arrhythmia and cardiomyopathy.⁶⁴ The most common type of arrhythmia is atrioventricular block, accounting for about half of patients, followed by ventricular tachycardia and supraventricular arrhythmia.^{65,66} Patients may be asymptomatic, especially in the early stage of the disease, or may experience palpitations, syncope, and even sudden cardiac death.⁶⁷ Heart failure due to cardiomyopathy is the first manifestation of cardiac sarcoidosis in 10-20% of patients.^{65,66} Heart failure can be seen in dilated cardiomyopathy with reduced ejection fraction (EF) and restrictive cardiomyopathy with preserved EF.⁶⁴

Diagnosis

In cases where a clinical-radiological pattern consistent with sarcoidosis is supported by histopathological detection of dense, primarily non-caseating, giant cell granulomas, a definitive diagnosis of sarcoidosis is made in the absence of any evidence of another granulomatous disease.⁶⁸ These include Lofgren's syndrome (arthritis, erythema nodosum,

Hilar Lymphadenopathy), Heerfordt syndrome (fever, parotid gland enlargement, anterior uveitis, facial paralysis), involvement of the lacrimal and parotid glands on Gallium-67 scintigraphy (panda sign) and right paratracheal and bilateral hilar involvement (lambda sign).⁶⁹

The best biopsy site depends on the accessibility of the lesion, the safety, and the potential yield of the procedure. Biopsy specimens of superficial lesions (skin lesions other than erythema nodosum, palpable peripheral lymph nodes, minor salivary gland, or visible conjunctival nodules) should be considered before other sites. If none of these factors is present, endobronchial and transbronchial lung biopsy with flexible bronchoscopy and lymph node sampling with endobronchial ultrasonography (EBUS) should be considered.⁷⁰ Due to its high diagnostic rate, transbronchial needle aspiration with EBUS has replaced mediastinoscopy to evaluate mediastinal and hilar lymph nodes.⁷¹

Bronchoalveolar lavage revealed moderate lymphocytosis in 80% of cases (20-50%) and a CD4/CD8 ratio higher than 3.5 in 50%. These findings are used to support the diagnosis of sarcoidosis.⁷²

Treatment

A personalized approach to patients seems imperative due to changing disease manifestations, significant variability in treatment response, and the wide range of treatment options.⁷³

The spontaneous remission rate is 55-90% in stage I, 40-70% in stage II, and 10-20% in stage III. Spontaneous remission is not seen in stage IV. Corticosteroids (CS) are the mainstay of pharmacologic treatment of pulmonary sarcoidosis due to their potent macrophage inhibition and lymphocyte activation. They are considered first-line therapy in sarcoidosis. There is insufficient evidence on the dose and duration of treatment. Recent data and accumulated clinical experience suggest that an initial dose (20-40 mg prednisone equivalent) should be given for 1 to 3 months, followed by re-evaluation, followed by a reduction to a maintenance dose of 5-10 mg/day, which may be prolonged for up to one year. In patients with mild disease such as skin lesions, anterior uveitis, or cough, topical steroid therapy may be all that is required. Oral corticosteroids are usually used in those with systemic and symptomatic disease. Systemic therapy is indicated for cardiac and neurologic involvement, ocular involvement not responding to treatment, and hypercalcemia. In

pulmonary and other extrapulmonary involvement, most physicians generally consider that progressive, symptomatic disease should be treated.⁷⁴

Cytotoxic/antimetabolite agents are also used in patients who progress despite CS or develop CS toxicity/side effects. Methotrexate is the most widely used and well-studied agent for pulmonary sarcoidosis. The usual dose is 10-25 mg orally or intramuscularly weekly. Maximum efficacy is reached 2-3 months after the start of treatment. Less commonly used agents are Azathioprine, Leflunomide, Mycophenolate, and Chloroquine/Hydroxychloroquine.⁷⁵

Another treatment option is biologic agents. They can be used in patients who cannot tolerate antimetabolites. Tumor necrosis factor (TNF) alpha inhibitors, particularly infliximab and adalimumab, are the most commonly used.⁷⁶

ULCERATIVE COLITIS

Ulcerative colitis (UC) is a chronic mucosal inflammation of unknown etiology that involves the colonic mucosa from the rectum to the proximal part. It is expected between 20-40 and 55-65 ages. It is less common in smokers. The most common site of involvement is the rectum. Inflammation almost always starts from the rectum and progresses towards the cecum. Inflammation is superficial, rarely crosses the lamina propria, and does not involve the serosa. Intestinal involvement is diffuse, with no intervening intact areas.⁷⁸ Pathologically, crypt abscesses are observed in the involved areas. Post-inflammatory pseudopolyps, epithelial goblet cell loss occurs during the healing period. In the chronic period, the appearance of lead pipe (loss of haustrations, smooth muscle thickening, shortening of the colon) may occur.

Bloody diarrhea is the most common presenting complaint in ulcerative colitis.⁷⁹ Rectal bleeding, tenesmus, and mucopurulent stools are common. Systemic symptoms such as fever, fatigue, night sweats, nausea, vomiting, and arthralgia may be present. Skin, joint, eye, liver, hematologic, and extraintestinal manifestations may occur. The most common laboratory pathology is iron deficiency anemia.⁸⁰ P-ANCA is positive as an autoantibody in 50-80% of cases.⁸¹

Complications may include fulminant colitis, toxic megacolon, risk of colon cancer, massive hemorrhage, perforation, thromboembolism, stricture, obstruction, and perianal disease.

Diagnosis

There are no clinical and laboratory findings that make the diagnosis alone. Increased acute phase reactants, significantly elevated CRP, increased sedimentation, leukocytosis, thrombocytosis, anemia, and hypoalbuminemia may be observed. Fecal lactoferrin and especially calprotectin in stool reflects intestinal inflammation.⁸²

An edematous, edematous fragile hyperemic granular mucosa that bleeds easily is typical on endoscopy. It is seen with superficial and irregular ulcers. Pseudopolyps are seen in the chronic phase. Radiologically, ulceration pseudopolyps and loss of haustrations can be seen in double contrast colon radiography.

Microscopic Features

The disease is limited to the mucosa and superficial submucosa. The deeper layers are intact except in fulminant disease. Two main histologic features of UC suggest chronicity and help to distinguish it from infectious or acute self-limiting colitis. First, the crypt structure of the colon is distorted; crypts may be cleft and reduced in number, often with a gap between the crypt base and the muscularis mucosa. Second, some patients have basal plasma cells and multiple basal lymphoid aggregates. Mucosal vascular congestion may be accompanied by edema, focal hemorrhage, and an inflammatory cell infiltrate, including neutrophils, lymphocytes, plasma cells, and macrophages. Neutrophils invade the epithelium, especially in crypts, causing cryptitis and, eventually, crypt abscesses.⁸³

Treatment

5-Aminosalicylic acid [Topical (rectal) or oral sulfasalazine or mesalamine], corticosteroids, and immunosuppressants (mercaptopurine and azathioprine can be used in maintenance therapy) are used for the treatment of ulcerative colitis. Cyclosporine is effective in acute and maintenance but is used in selected cases due to toxic effects. TNF alpha antagonists, infliximab, adalimumab, and golimumab (acute and maintenance), are used in treatment.⁸⁴

Proctocolectomy is performed in cases of toxic megacolon, perforation, non-stop bleeding, severe dysplasia on biopsy, and unresponsive to medical treatment.⁸⁵

CROHN'S DISEASE

It is a chronic granulomatous inflammatory disease with remissions and relapses that can involve the

gastrointestinal tract transmurally from the mouth to the anus. It can involve anywhere from the mouth to the anus (most commonly as ileocolitis -distal ileum and proximal colon are involved).⁸⁶ Involvement is segmental and transmural; the earliest macroscopic lesion is aphthous ulcer.⁸⁷ Dyspeptic complaints, abdominal pain, tenderness, and bloody diarrhea may occur in colon involvement. Weight loss and clubbing may be observed in patients. Systemic symptoms secondary to malabsorption are more common. Since the involvement is transmural, fistula, stricture, obstruction, and intrabdominal abscess may be observed, and colon cancer risk is increased. Erythema nodosum, peripheral arthritis, and ankylosing spondylitis are more common in Crohn's disease (CD).⁸⁸ Gallstones, osteomalacia, vitamin deficiencies, calcium oxalate stones, and obstructive uropathy are specific to CD and not expected in UC.⁸⁹ Sclerosing cholangitis and pyoderma gangrenosum are more common in UC.

Diagnosis

Increased acute phase reactants and significantly elevated CRP are observed. Fecal lactoferrin and especially calprotectin in stool reflects intestinal inflammation.⁸² Laboratory abnormalities are more prominent due to small bowel involvement and malabsorption. CT and MR enterography are primarily ordered for small bowel imaging. Capsule endoscopy is superior to radiologic methods. Hyperemic and edematous mucosa, deep linear ulcers between edematous areas, and rough mucosa (paving stone appearance) can be detected in the involved segments.^{90,91} In the differential diagnosis, infective agents, diverticulitis, ischemic colitis, radiation colitis, solitary rectal ulcer, NSAID-induced colitis, and drugs causing colitis (i.e., Mycophenolate mofetil and Ipilimumab) are included.

Microscopic Features

The earliest lesions are aphthous ulcerations and focal crypt abscesses. In focal crypt abscesses, scattered macrophage coagulations form noncaseating granulomas in all layers of the intestinal wall. Granulomas can occur in lymph nodes, mesentery, peritoneum, liver, and pancreas. Although granulomas are a pathognomonic feature of CD, they are rarely found in mucosal biopsies. Surgical resection reveals granulomas in about half of cases. Other histologic features of CD include the presence of submucosal or subserosal lymphoid aggregates, especially in

areas distant from the ulceration sites, macroscopic and microscopic jumping areas, and transmural inflammation characterized by fissures and sometimes fistulous tracts or local abscess formation deep into the intestinal wall.⁹²

Treatment

5-Aminosalicylic acid: Topical (rectal) or oral sulfasalazine or mesalamine; limited efficacy in ileal disease, given if colon involvement is present.

Corticosteroids, *Immunosuppression:* Mercaptopurine and azathioprine are used in maintenance therapy, and TNF alpha antagonists (infliximab, adalimumab, certolizumab) are used in both acute and maintenance therapy.⁹³

Monoclonal antibodies (anti-alpha four integrins): Natalizumab, ustekinumab, and vedolizumab are used for the treatment.

Antibiotics: Metronidazole and ciprofloxacin are preferred for suppressing active inflammation, perianal disease, and fistulizing cases.

Elemental diet: A liquid diet of amino acids and small nutrient molecules is given.

Surgery: It is performed in case of complications.

PRIMARY BILIARY CIRRHOSIS

It is an autoimmune disease characterized by progressive middle and slight intrahepatic bile duct damage.⁹⁴ The common bile ducts are not affected. Ninety percent are female and usually present clinically in middle age.

Histopathologic analysis of liver biopsies from PBS patients has shown that there are four distinct stages as the disease progresses. The earliest lesion is chronic nonsuppurative destructive cholangitis and is a necrotizing inflammatory process of the portal tracts. The middle and small bile ducts are infiltrated with lymphocytes and undergo constriction. Mild fibrosis and sometimes bile stasis may be seen. With progression, the inflammatory infiltrate is less prominent, but the number of bile ducts is reduced, and smaller bile ducts are proliferated. With increased periportal fibrosis, the fibrosis spreads and turns into bridging fibrosis. Eventually, cirrhosis may develop micronodular or macronodular.⁹⁵

Clinical Presentation

Non-specific symptoms such as fatigue, drowsiness, and arthralgia are seen in the early period. Pruritus is the first and most crucial symptom suggestive of hepatobiliary disease. Jaundice develops months

to years after pruritus.⁹⁶ Skin darkening, pruritus scars, bone pain, weight loss, fat malabsorption, and xanthomas may be seen. Hypercholesterolemia is present, but cardiovascular mortality is not increased because lipoprotein decreases. Portal hypertension and signs of cirrhosis occur in the later period. Sjogren's syndrome is the most common. CREST syndrome (Calcinosis, Reynaud, Esophageal hypomotility, Sclerodactyly, and Telangiectasia) and other autoimmune diseases may be associated.⁹⁷

Diagnosis

Cholestasis enzymes and direct bilirubin levels are increased. Bilirubin level is the most critical determinant of prognosis. Serum Ig M level is increased [98]. AMA is 95% positive and is the most essential serologic finding.⁹⁹ USG, MRCP, and ERCP are used to differentiate from pathologies causing extrahepatic cholestasis. A definitive diagnosis is made by demonstrating small- and medium-sized bile duct damage in a liver biopsy.

Treatment

Supportive treatment: Nutritional support, vitamin D, vitamin K support, calcium replacement, and cholestyramine for itching can be given.

Ursodeoxycholic acids slows the course of the disease, reduces symptoms, is more useful in early onset, and is not curative; obeticholic acid is recommended in unresponsive cases. Liver transplantation should be performed when liver failure develops.

RHEUMATOID ARTHRITIS

Rheumatoid Arthritis (RA) is a chronic inflammatory joint disease. Although its main target is synovial tissue, it is considered a connective tissue disease because of its involvement in many systems.¹⁰⁰ The female-to-male ratio is 3/1, which most commonly starts in the 25-55 age range. The clinic usually begins insidiously with mild joint pain and morning stiffness accompanied by general symptoms such as fatigue, subfebrile fever, and weight loss.

Joint Findings

Symmetrical polyarticular arthritis is characterized by pain, swelling, and increased temperature in the affected joint.¹⁰¹ Morning stiffness in the joint lasting longer than 30 minutes is characteristic and decreases with movement. It usually starts from the small joints of the hand (PIF and MCP) and foot (MTP). Large joints are involved later. It may involve the atlantoaxial

joint (C1-C2). The least expected joints involved in RA are DIP and intervertebral joints, except for the atlantoaxial (C1-C2) and sacroiliac joints.

Extra-articular involvement.¹⁰²

Skin: Rheumatoid nodules, vasculitis

Eye: Keratoconjunctivitis sicca, episcleritis

Mouth: Sikka symptoms

Respiratory: Pulmonary fibrosis, pleural effusion

Heart: Pericarditis, myocarditis

Neurological: Mononeuritis, entrapment neuropathies

Liver: Elevated transaminases

Hematologic: Anemia, thrombocytosis, leukocytosis, LAP, Felty syndrome (splenomegaly + neutropenia + rheumatoid arthritis)

The presence of extra-articular findings is a poor prognostic indicator.¹⁰³ Rheumatoid nodules may develop in 20-30% of RA patients. It is the most common extra-articular finding. They usually develop in periarticular structures, extensor surfaces, and other areas subjected to mechanical compression but can be found almost anywhere, including the pleura and menisci. They are frequently located in the olecranon bursa, proximal ulna, Achilles tendon, and arch head. The nodules are of varying size and consistency and rarely cause complaints but are sometimes disrupted by trauma and may become infected. They are almost always found in individuals with positive rheumatoid factor (RF). Histologically, three regions are seen in rheumatoid nodules. The central zone contains necrotic material consisting of collagen, non-collagen fibers, and cellular debris; the middle zone contains radiating macrophages expressing HLA-DR antigens; and the outer zone contains granulation tissue.¹⁰⁴

Non-specific markers of inflammation, such as erythrocyte sedimentation rate (ESR) and CRP, are associated with disease activity. RF is positive in 75% of RA patients. Anti-CCP is positive in 75-80% of RA patients, with a specificity of 95%.¹⁰⁵ RF and/or anti-CCP positivity in RA is associated with more severe joint disease, extra-articular involvement, and poor prognosis.¹⁰⁵ Anti-nuclear Antibody (ANA) and Antineutrophil cytoplasmic antibodies (particularly P-ANCA) are positive in 30% of cases.

Treatment

NSAIDs, Corticosteroids, Conventional Disease-modifying anti-rheumatic drugs (DMARDs); Methotrexate, sulfasalazine, antimalarial drugs,

Leflunomide, Biological DMARDs; TNF alpha inhibitors; Infliximab, Adalimumab, Golimumab, Etanercept, Certolizumab, and Anakinra, Rituximab, Abatacept, Tocilizumab, Tofacitinib are used in selected cases.¹⁰⁶

WEGENER'S GRANULOMATOSIS

Wegener's granulomatosis is characterized by granulomatous upper and lower respiratory tract vasculitis with glomerulonephritis.¹⁰⁷ Typical histopathological findings of Wegener's granulomatosis are granuloma formation with necrotizing vasculitis of small arteries and veins.¹⁰⁸ In the lungs, multiple bilateral, cavitating nodular infiltrates typically occur.

Biopsy findings almost always show typical necrotizing granulomatous vasculitis. Upper respiratory tract lesions, especially those in the sinuses and nasopharynx, typically involve inflammation, necrosis, and granuloma formation. Vasculitis may accompany these findings.

The upper respiratory tract is involved in 75% of patients with Wegener's granulomatosis.¹⁰⁸ Patients often present with paranasal sinus pain and drainage, purulent or bloody nasal discharge. Nasal mucosal ulcers may also be presenting symptoms. Perforation of the nasal septum may occur.¹⁰⁹ Serous otitis media may develop due to obstruction of the eustachian tube. Subglottic tracheal stenosis due to active disease or scarring develops in approximately 16% of patients and causes severe airway obstruction.

Pulmonary involvement may present with asymptomatic infiltrates or lead to coughing, hemoptysis, dyspnea, or discomfort in the chest. Lung involvement occurs in 85-90% of patients.¹¹⁰ Endobronchial obstruction and atelectasis may develop during active disease or after fibrosis scarring.

Ocular involvement occurs in 52% of patients.¹¹¹ Involvement ranges from mild conjunctivitis to dacryocystitis, episcleritis, scleritis, granulomatous sclerouveitis, ciliary vasculitis, and retro-orbital mass lesions causing proptosis.

The sensitivity of the C-ANCA test for Wegener's granulomatosis ranges from 34% to 92%, and the specificity from 88% to 100%.¹¹²

CHURG-STRAUSS SYNDROME

Necrotizing vasculitis of Churg-Strauss syndrome affects small and medium-sized muscular arteries, capillaries, veins, and venules.¹¹³ The characteristic histopathological feature is a granulomatous reaction

in the tissues and even in the vessel walls. These granulomatous structures are often accompanied by eosinophilic tissue infiltration.¹¹⁴ This phenomenon can occur in any organ in the body, the most commonly affected organ being the lung. The skin, cardiovascular system, kidney, peripheral nerves, and gastrointestinal tract are also commonly involved.

Although the exact pathogenesis of the disease is unknown, the strong association with asthma and the clinical and pathologic findings of eosinophilia, granulomas, and vasculitis suggest that an exaggerated immunologic phenomenon is responsible for the onset of the disease.

GIANT CELL ARTERITIS

The most commonly involved artery in giant cell arteritis is the temporal artery. In fact, most patients have a silent systemic involvement involving multiple medium and large arteries.¹¹⁵

Histopathologic examination reveals panarteritis with inflammatory mononuclear cell infiltrates with frequent giant cell structures within the vessel wall.¹¹⁶ Pathophysiological findings in organs are caused by ischemia associated with the involved vessels.¹¹⁷

CHRONIC BERYLLIUM DISEASE

Beryllium is a lightweight, stretchable, hard metal with good electrical conductivity. The cooling ability of neutrons with water is vital in controlling nuclear reactions. Although beryllium causes acute pneumonitis, it is often associated with chronic granulomatous inflammation like sarcoidosis.¹¹⁸

If occupational beryllium exposure in industries such as high-tech electricity and ceramics is not specifically questioned in a patient with sarcoidosis, the relationship between occupational exposure and etiology is missed.

The evidence distinguishing chronic beryllium disease from sarcoidosis demonstrates a beryllium-specific cellular immune response (delayed hypersensitivity). The test that often provides this evidence is the Beryllium Lymphocyte Proliferation test.^{119,120}

HYPERSENSITIVITY PNEUMONITIS

Hypersensitivity pneumonitis, or extrinsic allergic alveolitis, is a non-IgE-mediated hypersensitivity reaction resulting from repeated inhalation of organic dust particles or various chemical substances.¹²¹

Dust (arising in agriculture), bioaerosols, microorganisms (fungal, bacterial, or protozoal), and

some reactive chemical species cause the disease.

The acute response after antigen inhalation is a non-specific diffuse pneumonia characterized by mononuclear cell and neutrophil infiltration in the bronchioles, alveoli, and interstitium. With repeated exposures, a subacute stage develops with lymphocyte infiltration in the bronchioles. The chronic stage develops within three weeks and is characterized by non-caseous epithelioid granulomas. In long-term exposures, progressive fibrosis and bronchiolitis obliterans may develop. In late chronic processes, fibrosis may result in honeycomb lung with histopathology similar to usual interstitial pneumonia.^{122,123}

Ethical Approval

The ethical approval is not required for the reviews

Authors' Contribution

Study Conception: HK, MİK,NK; Study Design: HK, MİK,NK; Supervision: HK, MİK,NK; Data Collection and/or Processing: HK, MİK,NK; Analysis and/or Data Interpretation: HK, MİK,NK; Literature Review: HK, MİK,NK; Critical Review: HK, MİK,NK; Manuscript preparing: HK, MİK,NK.

REFERENCES

1. James DG. A clinicopathological classification of granulomatous disorders. *Postgrad Med J.* 2000 Aug;76(898):457-65.
2. Zumla A, James DG. *Granulomatous Infections: Etiology and Classification, Clinical Infectious Diseases*, Volume 23, Issue 1, July 1996, Pages 146–158,
3. Flamm SL. Granulomatous liver disease. *Clinics in liver disease.* 2012;16.2: 387-396.
4. Bennett JE, Dolin R, Blaser MJ. *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases E-Book: 2-Volume Set.* Elsevier health sciences, 2019.
5. Sunnetcioglu A, Sunnetcioglu M, Binici I, Baran AI, Karahocagil MK, Saydan MR. Comparative analysis of pulmonary and extrapulmonary tuberculosis of 411 cases. *Annals of clinical microbiology and antimicrobials*, 2015;14, 34.
6. Duguid JP. Expulsion of Pathogenic Organisms from Respiratory Tract. *Br Med J.* 1946 Feb 23;1(4442):265-8.
7. Turkish Respiratory Research Association. Available at: <https://solumum.org.tr/>. Accessed March 25, 2024.
8. Özçelik HU. Pediatric Face of Tuberculosis. *Journal of Lung Health and Intensive care*; 2021: pp. 25-35.

9. Kocaman Karğı A. Detection of latent tuberculosis infection in hospital workers. 2010.
10. Republic of Turkey Ministry of Health Tuberculosis Diagnosis and Treatment Guide; 2019: pp. 12.
11. Raval AA, Goswami H, Parikh U, Shah P, Yadav KS. Extrapulmonary tuberculosis at tertiary health care center: a review. *Journal of Infectious Diseases Letters*, ISSN, 2013;0976-8904.
12. Ceyhan İ, Şimşek H, Tarhan G. Comparison and evaluation of 2% Ogawa medium with Löwenstein-Jensen medium in the diagnosis of tuberculosis. 2012.
13. Rieder HL, Chadha VK, Nagelkerke NJ, Van Leth F, Van Der Werf MJ. Guidelines for conducting tuberculin skin test surveys in high-prevalence countries. *The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease*. 2011 Jan;15 Suppl 1:S1-25.
14. Iseman MD. Tuberculosis guide for clinicians. Translated by: Ozkara Ş. İstanbul Nobel Book Stores. 2002.
15. Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. *Clin Infect Dis*, 2017;64(2):111-115.
16. Aslan R. The comparison of microscopy, culture and molecular methods for diagnosis of tuberculosis. 2015.
17. Seymen FB. Examination of treatment side effects in pediatric tuberculosis cases followed between 2016-2021 at Uludağ University Department of Pediatric Infectious Diseases (Doctoral dissertation, Bursa Uludag University (Turkey)). 2022.
18. Çimen P, Kayaalp İ, Ayrancı A, Güçlü SZ. A Case of lung Tuberculosis with atypical radiological findings. *Izmir Chest Hospital Journal*, 2014;28(3), 181-185.
19. Okutan UDO. Lung Tuberculosis in adults. 2003.
20. Uçar ZZ, Çakan A, Dereli Ş, Özsöz A, Soy Ö. Investigation of the frequency of parenchymal lesions in tuberculous pleurisy cases using high-resolution thorax computed tomography. 2002.
21. Republic of Turkey Ministry of Health Communicable Diseases Notification and Reporting System Circular; 2015: pp. 18.
22. Kalem E, Açar E. Use of thioureas in the treatment of tuberculosis. *Anadolu Bil Vocational School Journal*, 2022; 16(64), 239-262.
23. Özkara Ş, Arpaz S, Özkan S, Aktaş Z, Örsel O, Ecevit H. Directly observed therapy (DOT) in the treatment of tuberculosis. *Respiratory Diseases*. 2003;14(2), 150-7.
24. Kuyucuoğlu Y. Brucella disease. *Kocatepe Veterinary Journal*, 2011;4(1), 57-64.
25. Corbel MJ. Brucellosis in humans and animals. World Health Organization. 2006.
26. Polat M, Kara SS, Tırhış Ö, Tapısız A, Tezer H. A Case of Fever of Unknown Origin with Brucellosis and the Prozone Phenomenon. *Journal of Pediatric Disease*, 2013;7(1,EK):29-31.
27. Günal Ö, Bahadır-Ülger FE, Barut Ş, Ülger A. Osteoarticular Brucellosis. *Klimik Journal*, 2011;24(2).
28. Sayılır K, Kutlu SS, Baykam N, Eren Ş, Çelikbaş AK, Dokuzoğuz B. Two human cases of brucellosis resulting in abortion. *Journal of Infection*, 2003;17(3), 345-348.
29. Uluğ M, Can-Uluğ N. Evaluation of 78 Cases with Brucellosis. *Klimik Journal*, 2010;23(3).
30. Dizer U, Beker CM, Çiçek H, Güner ÖR, Zeren İ, Pahsa A. Investigation of the effectiveness of brucellosis diagnostic methods. *Uludağ University Faculty of Medicine Journal*, 2005;31(2), 87-93.
31. Evirgen Ö, Motor VK. Brucellosis. *Journal of Experimental and Clinical Medicine*, 2013;29(3s), 149-154.
32. Yeni DK. Tularemia. *Etlik Journal of Veterinary Microbiology*, 2013;24(1), 20-25.
33. Kılıç S, Yeşilyurt M. Tularemia: An Overview of Current Treatment Options. *Klimik Journal*, 2011;24(1)
34. Korkmaz P, Naz H, Güçlüyener MN, Çağlan-Çevik F, Aykın N. Cat scratch disease: Case report. *Klimik Journal*, 2011;24(2), 116-8.
35. Çelebi B. Bartonella henselae and infections. *Microbiol Bull*, 2008;42(1), 163-75.
36. Bölük G, Mıstık R, Helvacı S, Yalçınkaya U, Nazlıoğlu HÖ. Three probable cat scratch disease cases treated with azithromycin. 2011.
37. Ayvaz G, Kaygusuz S. Current approaches in the diagnosis and treatment of sexually transmitted diseases. *Kırıkkale University Faculty of Medicine Journal*, 2021;23(1), 143-156.
38. Öztoklu İ, Yücel A. Chlamydia trachomatis infections. *Ankara Medical Journal*, 2012; 12(1), 32-36.
39. Günal Ö, Barut Ş. Q Fever. *Gaziosmanpaşa University Faculty of Medicine Journal*, 2011;3(3), 28-29.
40. Bucuk PS, Sirmatel FA. Forgotten Zoonotic Disease: Q Fever. *Abant Medical Journal*, 2022;11(1), 132-142.
41. Saltoğlu N. Invasive Mycoses: Clinical Appearances. *Flora Journal of Infectious Diseases and Clinical Microbiology*, 2006;11(4), 169-180.
42. Bezmialem Vakif University Department of Infectious Diseases and Clinical Microbiology. Turkish Infectious Diseases and Clinical Microbiology Specialization Association. HIV-related fungal infections. Available at: <https://www.ekmud.org.tr/>. Accessed March 25, 2024.
43. Hunninghake GW. Statement on sarcoidosis. *Am J Respir Crit. Care Med*, 1999;160, 736-755.
44. Çetinoğlu ED. Epidemiology of Interstitial Lung Disease in Turkey and the World. *Current Chest Diseases Series*, 2014;2(3), 257-262.

45. Musellim B, Kumbasar OO, Ongen G, et al. Epidemiological features of Turkish patients with sarcoidosis. *Respir Med.* 2009;103(6):907-912.
46. Yönetimine LH, Zengin F. Contribution of lymphocyte-dominant bronchoalveolar lavage to disease management and treatment in interstitial lung diseases. 2020.
47. Kutbay Özçelik H, Bayram M, Büyükbaşılı NP, et al. Sarcoidosis with Pleural Involvement. 2014.
48. Hamzeh N. Sarcoidosis. *The Medical clinics of North America*, 2011,95(6), 1223–1234.
49. Judson MA. The Symptoms of Pulmonary Sarcoidosis. *Journal of clinical medicine*, 2023;12(18), 6088.
50. Keir G, Wells AU. Assessing pulmonary disease and response to therapy: which test?. In *Seminars in respiratory and critical care medicine*, (2010, August; Vol. 31, No. 04, pp. 409-418). © Thieme Medical Publishers.
51. Abakay Ö. Innovations in Sarcoidosis Diagnosis and Treatment. *Current Chest Disease Series*, 2014; 2(3), 379-86.
52. Salazar A, Mana J, Corbella X, Albareda JM, Pujol R. Splenomegaly in sarcoidosis: a report of 16 cases. *Sarcoidosis*, 1995;12(2), 131-134.
53. Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. *Sarcoidosis, vasculitis, and diffuse lung diseases: official journal of WASOG*, 2012;29(2), 119-127.
54. Tatoğlu MS, Gülbaran Z. Frequency of pulmonary hypertension in sarcoidosis patients. 2020.
55. Ungprasert P, Tooley AA, Crowson CS, Matteson EL, Smith WM. Clinical characteristics of ocular sarcoidosis: a population-based study 1976–2013. *Ocular immunology and inflammation*, 2019;27(3), 389-395.
56. Cozier YC, Berman JS, Palmer JR, Boggs DA, Serlin DM, Rosenberg L. Sarcoidosis in black women in the United States: data from the Black Women’s Health Study. *Chest*, 2011;139(1), 144-150.
57. Lynch III JP, Kazerooni EA, Gay SE. Pulmonary sarcoidosis. *Clinics in Chest Medicine*, 1997;18(4), 755-785.
58. Morimoto T, Azuma A, Abe S, et al. Epidemiology of sarcoidosis in Japan. *European Respiratory Journal*, 2008;31(2):372-379.
59. Deutsch-Link S, Fortuna D, Weinberg EM. A comprehensive review of hepatic sarcoid. In *Seminars in Liver Disease*, (2018, August, Vol. 38, No. 03, pp. 284-297). Thieme Medical Publishers.
60. Ungprasert P, Crowson CS, Simonetto DA, Matteson EL. Clinical characteristics and outcome of hepatic sarcoidosis: a population-based study 1976–2013. *Official journal of the American College of Gastroenterology ACG*, 2017;112(10), 1556-1563.
61. Ungprasert P, Matteson EL. Neurosarcoidosis. *Rheumatic Disease Clinics*, 2017;43(4), 593-606.
62. Berliner AR, Haas M, Choi MJ. Sarcoidosis: the nephrologist’s perspective. *American Journal of Kidney Diseases*, 2006;48(5), 856-870.
63. Loncope WT. A study of sarcoidosis: Based on a combined investigation of 160 cases, including 30 autopsies from the Johns Hopkins Hospital and Massachusetts General Hospital. *Medicine*, 1952;31, 1-132.
64. Hamzeh N, Steckman DA, Sauer WH, Judson MA. Pathophysiology and clinical management of cardiac sarcoidosis. *Nature Reviews Cardiology*, 2015;12(5), 278-288.
65. Kandolin R, Lehtonen J, Airaksinen J, Vihinen T, Miettinen H, Ylitalo K, et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. *Circulation*, 2015; 131(7), 624-632.
66. Chapelon-Abric C, de Zuttere D, Duhaut P, Veyssier P, Wechsler B, de Gennes C, et al. Cardiac sarcoidosis: a retrospective study of 41 cases. *Medicine*, 2004;83(6), 315-334.
67. Hu X, Carmona EM, Yi ES, Pellikka PA, Ryu J. Causes of death in patients with chronic sarcoidosis. *Sarcoidosis, vasculitis, and diffuse lung diseases: official journal of WASOG*, 2016;33(3), 275-280.
68. Yserbyt J, Wells AU. Sarcoidosis: pulmonary manifestations and management. *Pulmonary Manifestations of Systemic Diseases; European Respiratory Society (ERS): Lausanne Switzerland*, 2019;404-418.
69. In Özlü T, Metintaş M, Karadağ M, Kaya A, eds. *Respiratory System and Diseases Basic Reference Book*. Istanbul. Istanbul Medical Bookstore; 2010: pp. 813-817.
70. Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Müller-Quernheim J. Sarcoidosis. *Lancet (London, England)*, 2014;383(9923), 1155–1167.
71. Wessendorf TE, Bonella F, Costabel U. Diagnosis of sarcoidosis. *Clinical reviews in allergy & immunology*, 2015;49, 54-62.
72. Costabel U, Bonella F, Ohshimo S, Guzman J. Diagnostic modalities in sarcoidosis: BAL, EBUS, and PET. In *Seminars in respiratory and critical care medicine*, (2010, August; Vol. 31, No. 04, pp. 404-408). © Thieme Medical Publishers.
73. Gibson GJ, Prescott RJ, Muers MF, Middleton WG, Mitchell DN, Connolly CK, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. *Thorax*, 1996;51(3), 238-247.
74. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association

- of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. *Am J Respir Crit Care Med.* 1999 Aug;160(2):736-55.
75. Paramothayan S, Lasserson T. Treatments for pulmonary sarcoidosis. *Respiratory medicine*, 2008;102(1), 1-9.
 76. Ungprasert P, Ryu JH, Matteson EL. Clinical manifestations, diagnosis, and treatment of sarcoidosis. *Mayo Clinic Proceedings: Innovations, Quality & Outcomes*, 2019;3(3), 358-375.
 77. Hartavi M. Investigation of Cytokine Signal Suppressor (SOCS)-1 1478 CA/DEL Gene Polymorphism in Patients Diagnosed with Ulcerative Colitis (Doctoral dissertation, Bursa Uludag University (Turkey)). 2012.
 78. Peppercorn MA, Kane SV. Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults. *UpToDate* (Accessed on December 2014). 2020.
 79. Ozin Y, Kilic MZ, Nadir I, Cakal B, Disibeyaz, S, Arhan M, et al. Clinical features of ulcerative colitis and Crohn's disease in Turkey. *J Gastrointest Liver Dis*, 2009;18(2), 157-62.
 80. Kösel E. Nutrition in ulcerative colitis. *Current Gastroenterology*, 2016;20(3), 263-266.
 81. Broekroelofs J, Mulder AHL, Nelis GF, Westerveld BD, Cohen Tervaert JW, et al. Antineutrophil cytoplasmic antibodies (ANCA) in sera from patients with inflammatory bowel disease (IBD) Relation to disease pattern and disease activity. *Digestive diseases and sciences*, 1994;39, 545-549.
 82. Hasanova G, Barutçuoğlu B, Üna NG, Ak G, Özütemiz Ö. Early Prediction of Disease Activity in Crohn's Patients in Clinical Remission. 2019.
 83. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. *British medical journal*, 1955;2(4947), 1041.
 84. Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomized controlled trial. *Gut*, 2011;60(6), 780-787.
 85. Sandborn WJ. Pouchitis following heal pouch-anal anastomosis: definition, pathogenesis, and treatment. *Gastroenterology*, 1994;107(6), 1856-1860.
 86. Mercimek K. Epidemiological characteristics of inflammatory bowel diseases in the Thrace region. 2010.
 87. Göksel S. Pathological Features of Crohn's Disease. *Cerrahpaşa Medical Journal*, 2009;40(3), 103-120.
 88. Smale S, Natt RS, Orchard TR, Russell AS, Bjarnason I. Inflammatory bowel disease and spondylarthropathy. *Arthritis & Rheumatism: Official Journal of the American College of Rheumatology*, 2001;44(12), 2728-2736.
 89. Kul S. The role of small intestine bacterial overgrowth in inflammatory bowel diseases. 2018.
 90. Scotiniotis I, Rubesin SE, Ginsberg GG. Imaging modalities in inflammatory bowel disease. *Gastroenterology Clinics of North America*, 1999;28(2), 391-421.
 91. Şenkal İV. The effect of mesenchymal stromal cells on inflammatory and pro-inflammatory cytokines in the Crohn's disease model and their use in treatment. 2010.
 92. Şahin B. Retrospective analysis of anti-TNF therapy in inflammatory bowel diseases (Doctoral dissertation, Bursa Uludag University (Turkey)). 2018.
 93. Doecke JD, Hartnell F, Bampton P, Bell S, Mahy G, Grover Z. et al. Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study. *Alimentary Pharmacology & Therapeutics*, 2017;45(4), 542-552.
 94. De Medeiros CR, Setúbal DC. Autoimmune hemolytic anemia as a complication of primary biliary cirrhosis. 2004.
 95. Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J (Eds.), *Harrison's Principles of Internal Medicine*; 2017: pp. 1974.
 96. Sezer BT, Sezer, Ö, Oygen Ş, Çalışkan CK, Borlu F. Primary sclerosing cholangitis without icterus in a seventeen-year-old male patient-case report. 2011.
 97. Angulo P, Lindor KD. Primary sclerosing cholangitis. *Hepatology*, 1999;30(1), 325-332.
 98. Tekin F, Görümlü G, Yüce G, Soydan S, et al. Coexistence of multiple myeloma and primary biliary cirrhosis: A case report. *Academic Journal of Gastroenterology*, 2008;7(2).
 99. Sherlock S. Primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune cholangitis. *Clinics in Liver Disease*, 2000;4(1), 97-113.
 100. Suzuki N. Kansas G Engleman EG: Lymphocytes. *Arthritis and allied conditions*. McCarty DJ, Koopman WJ (Eds). Lea and Febiger, 1993;pp. 377-387.
 101. Bozkurt A, Gök M. Effects of steroid and methotrexate treatment on cardiac functions in patients with rheumatoid arthritis. 2016.
 102. Boz M, Ülgen E, Ergüney M, Ünal N, Pişkinpaşa E. Extra-articular symptoms in rheumatoid arthritis. *Istanbul Medical Journal*, 2006;1, 26-31.
 103. Göksoy T. Diagnosis and treatment of rheumatic diseases. Yüce Advertising Publishing Distribution. 2002.
 104. Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J (Eds.), *Harrison's Principles of Internal Medicine*; 2017: pp. 2087.
 105. Sertpoyraz FM, Köse Ş, Öztürk Y. The relationship between rheumatoid factor and anti-CCP in patients with rheumatoid arthritis. *Tepecik Training Hospital Journal*, 2013;23(2), 93-6.
 106. Demirel A, Kırnap M. Traditional and current approaches in rheumatoid arthritis treatment. *Journal of Health Sciences*, 2010;19(1), 74-84.

107. Şahin S, Balcan B, Kızıldaş Ş, Aydın M. A Case of Wegener's Granulomatosis Complicated with Brain Abscess Due to Nocardia. *Journal of Academic Research in Medicine*, 2016;6(2).
108. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. *Annals of Internal Medicine*, 1992;116(6), 488-498.
109. Vignes S, Chaillet M, Cabane J, Piette JC. Perforation de la cloison nasale et maladies systémiques. *La Revue de médecine interne*, 2002;23(11), 919-926.
110. Ergün P, Biber Ç, Erdoğan Y, et al. Wegener's granulomatosis: evaluation of eight cases. *Journal of Tuberculosis and Thorax*, 2001;49(3), 477-82.
111. Leavitt RY, Fauci AS. Less common manifestations and presentations of Wegener's granulomatosis. *Current opinion in rheumatology*, 1992;4(1), 16-22.
112. Rao JK, Weinberger M, Oddone EZ, Allen NB, Landsman P, Feussner JR. The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis: a literature review and meta-analysis. *Annals of Internal Medicine*, 1995;123(12), 925-932.
113. Mouthon L, Dunogue B, Guillevin L. Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg–Strauss syndrome). *Journal of autoimmunity*, 2014;48, 99-103.
114. Çelik Y, Kızıltan G, Yaldiran A, Büge ÖZ. Development of mononeuritis multiplex in a case with bronchial asthma: Churg-Strauss syndrome. *Cerrahpaşa Medical Journal*, 2014;31(2).
115. Rahman W, Rahman FZ. Giant cell (temporal) arteritis: an overview and update. *Survey of ophthalmology*, 2005;50(5), 415-428.
116. Coşkun Ö, Gül HC, Savaşçı Ü, Durmaz A, Eyigün CP. A case of fever with an unknown reason, diagnosed with temporal arteritis, with positional vertigo. *Gazi Medical Journal*, 2009;20(1).
117. Kiki İ, Gündoğdu M, Erdem F, Sarı RA. A Case of Temporal Arteritis with Atypical Clinical Presentation. *Journal of Turgut Ozal Medical Center*, 2007;14(3), 207-210.
118. Şenay EH. HLA genotyping in cardiac and noncardiac involvement of sarcoidosis patients. 2020.
119. Fireman E, Haimsky E, Noiderfer M, Priel I, Lerman Y. Misdiagnosis of sarcoidosis in patients with chronic beryllium disease. *Sarcoidosis, vasculitis, and diffuse lung diseases: official journal of WASOG*, 2003;20(2), 144-148.
120. Handa T, Nagai S, Kitaichi M, Chin K, Ito Y, Oga T, et al. Long-term complications and prognosis of chronic beryllium. *Sarcoidosis Vasculitis and Diffuse Lung Diseases*, 2009;26, 24-31.
121. Küpeli E, Karnak D. Hypersensitivity pneumonitis. *Tuberculosis and Thorax Journal*, 2011;59(2), 194-204.
122. Costabel U, Guman J. Less common diseases: hypersensitivity pneumonitis. *Diffuse Lung Disease. A Practical Approach*. London: Arnold, 2004;203-12.
123. Lacasse Y, Selman M, Costabel U, Dalphin JC, Ando M, Morell F, et al. Clinical diagnosis of hypersensitivity pneumonitis. *American journal of respiratory and critical care medicine*, 2003;168(8), 952-958.

The role of autoimmune thyroid disorders in patients with alopecia areata

Hatice Nihal Şahin¹, Adnan Görgülü²

¹Department of Dermatology and Venereology, Bucak State Hospital, Burdur, Türkiye

²Department of Dermatology and Venereology, Trakya University Faculty of Medicine, Edirne, Türkiye

ABSTRACT

Objectives: The aim of this study was to investigate the association of thyroid autoimmunity with alopecia areata (AA) by examining thyroid stimulating hormone (TSH) and thyroid autoantibody levels. In addition, to compare the epidemiologic data obtained with the data of our country.

Methods: Our study was organized as a cross-sectional, retrospective study. The study was performed on patients between the ages of 2-65 years who were admitted to our outpatient clinic between 01.01.2008 and 31.12.2011, who were clinically or histopathological diagnosed with AA, examined for etiology and thyroid autoantibodies were requested. Patients under two years of age and over 65 years of age, patients with no thyroid autoantibodies and pregnant patients were excluded. Results were expressed as mean±standard deviation and median values. Mann-Whitney U test was used to compare TSH, anti-TG antibody (Anti-TG) and anti-TPO (Anti-TPO) antibody values in the variables of nail involvement, psychiatry, comorbidity and family history. Spearman correlation analysis was used to examine the relationships between age and disease duration and TSH, Anti-TPO and Anti-TG variables.

Results: In our study, 65 (42.8%) of 152 patients were female and 87 (57.2%) were male. The age of the patients was 26.5±14.6 years. The mean age of females was 27.5±14.4 and 25.7±14.9 in males. Elevated thyroid autoantibodies were found in a total of 29 patients, 21 of whom were female and 8 of whom were male. Of these 29 patients, 10 had hypothyroidism, 2 had chronic thyroiditis and 3 had toxic multinodular goiter. 14 patients did not return after the examination at the internal medicine outpatient clinic, so the diagnosis of thyroid disease could not be reached. The mean TSH, Anti-TG and Anti-TPO values were 2.27±1.57, 29.2±99 and 71.5±2.2, respectively. When these values were analyzed separately as men and women, they were found to be 2.6±2.02, 41.8±1.23 and 134±2.8 in women and 1.99±1.03, 19.8±75.6 and 24.5±1.32 in men. There was a significant difference between men and women in terms of Anti-TG and Anti-TPO values (p=0.011 and p=0.001, respectively). A significant correlation was found between disease duration and Anti-TPO positivity (p=0.045); however, a similar relationship was not found between disease duration and Anti-TG positivity (p=0.34).

Conclusions: As a result of this study, although there was a significant correlation between anti-TPO and duration of AA, the association between thyroid autoimmunity and AA was not found to be statistically significant. This may be due to the fact that humoral autoimmunity plays a role in thyroid autoimmunity and primarily cellular autoimmunity plays a role in AA. In addition, the epidemiologic data of our study were similar to the data of studies conducted in our country.

Keywords: Alopecia areata, thyroid autoantibodies, autoimmune thyroid disorders, autoimmune diseases, dermatology, skin and venereal diseases

Received: January 22, 2024; Accepted: February 21, 2024; Published Online: April 29, 2024

How to cite this article: Şahin HN, Görgülü A. The role of autoimmune thyroid disorders in patients with alopecia areata. DAHUDER MJ 2024,4(2):54-60. DOI: 10.56016/dahudermj.1418216

Address for correspondence: Hatice Nihal Şahin, Department of Dermatology and Venereology, Bucak State Hospital, Bucak, Burdur, Türkiye
E-mail: nihalcicek15@hotmail.com

Available at <http://dergipark.org.tr/en/pub/dahudermj>

Alopecia areata (AA), a complex, multifactorial and autoimmune disease, is the second most common form of scarless hair loss after androgenetic alopecia. AA appears as sharply circumscribed round or oval areas with no visible inflammation on the skin, appearing suddenly on hair anywhere on the body, especially on the scalp. It may regress spontaneously or progress and affect the entire scalp and other body hair. The prevalence of the disease is 1 in 1000 worldwide, and this rate increases to 1-2% in those who apply to dermatology outpatient clinics. It affects 147 million people worldwide. The lifetime incidence is 2%. Most patients are younger than 30 years of age and only 20% are 40 years or older. It can occur at any age, regardless of race or gender, but is more common in young adults. AA leads to a reduced quality of life. It increases many psychosocial problems, especially in family and work life. The likelihood of autoimmune and systemic diseases is higher in patients with AA. Common cytokine response, similar immune cell types and similar genetic structures are thought to play a role in this.¹⁻⁵ The etiopathogenesis of AA has been linked to genetics, epigenetics, oxidative stress, immunology, microbiota, microbiome and allergy.⁶ There is a lymphocytic infiltration involving the peribulbar anagen terminal hairs, which is described histopathologically as a “swarm of bees”, but in the chronic phase almost all the follicles are in the telogen phase.⁶

AA was associated with increased odds of the following overall categories of disease in descending order: ocular (OR 3.15), thyroid (OR 3.13), connective tissue and autoimmune (OR 2.28), neurologic (OR 2.06), dermatologic (OR 1.94), atopic (OR 1.82). Alopecia Areata has been shown to be associated with vitamin D deficiency. As in Behcet’s disease, a chronic vasculitis of unknown cause, and other autoimmune diseases.⁷⁻¹⁰

AA was associated with lower rates of irritable bowel syndrome, acne vulgaris and some cancers (colorectal, non-melanoma skin cancers, bladder, hepatocellular, stomach) compared to healthy volunteers. However, data on these conditions were obtained from a small number of studies.⁹

The possible association of AA with autoimmune diseases comes to mind; it’s possible that there is an association with thyroid disease, which is also known to be associated with autoimmunity. There are some studies in the literature on this subject, but there is a new need for screening in both patient groups to

investigate the association of AA with thyroid diseases and to raise awareness. The aim of this study was to investigate the association of thyroid autoimmunity with AA by examining thyroid stimulating hormone (TSH) and thyroid autoantibody levels. In addition, to compare the epidemiologic data obtained with the data of our country.

METHODS

Our study was organized as a cross-sectional, retrospective study. Approval was obtained from Trakya University Faculty of Medicine Ethics Committee on 21.12.2011 with decision number 14/138 and protocol number 15789. SPSS 19 statistical package program was used for statistical analysis. The study was performed on patients between the ages of 2-65 years who were admitted to our outpatient clinic between 01.01.2008 and 31.12.2011, who were clinically or histopathological diagnosed with AA, examined for etiology and thyroid autoantibodies were requested. Patients under two years of age and over 65 years of age, patients with no thyroid autoantibodies and pregnant patients were excluded. 37,000 patients were screened. Three hundred forty-three AA patients were identified. A total of 152 patients who met these conditions were included in this study.

Results were expressed as mean \pm standard deviation and median values. Mann-Whitney U test was used to compare TSH, anti-TG antibody (Anti-TG) and anti-TPO (Anti-TPO) antibody values in the variables of nail involvement, psychiatry, comorbidity and family history. Spearman correlation analysis was used to examine the relationships between age and disease duration and TSH, Anti-TPO and Anti-TG variables.

RESULTS

In our study, 65 (42.8%) of 152 patients were female and 87 (57.2%) were male. Elevated thyroid autoantibodies were found in a total of 29 patients, 21 of whom were female and 8 of whom were male. Of these 29 patients, 10 had hypothyroidism, 2 had chronic thyroiditis and 3 had toxic multinodular goiter. 14 patients did not return after the examination at the internal medicine outpatient clinic, so the diagnosis of thyroid disease could not be reached.

The ages of the patients ranged between 2-64 years

and the mean age was 26.5 ± 14.6 years. The mean age of females was 27.5 ± 14.4 and 25.7 ± 14.9 in males (figure 1).

Patch type AA was seen in 150 cases and alopecia totalis (AT) was present in 2 cases. One of the AT patients was female and one was male. Scalp was involved in 115 patients (74.7%), beard in 18, scalp and beard in 8, scalp and eyebrows or eyelashes in 6, and only eyebrows or eyelashes in 5. Nail involvement was found in only 12 (7.9%) patients, but not in 140 (92.1%) patients.

While 51 (33.6%) of the patients had comorbidities, 101 (63.4%) did not. Of those with comorbidities, 31 had psychiatric, 15 thyroid, 2 acne vulgaris, 2 vitiligo, and one had both psychiatric and thyroid diseases. Family history was present in 17 (11.2%) and absent in 135 (88.8%) of 152 patients. Ophiasis was present in 5 patients and both ophiasis and nevus flammeus were present in 1 patient.

The mean TSH, Anti-TG and Anti-TPO values were 2.27 ± 1.57 , 29.2 ± 99 and 71.5 ± 2.2 , respectively. When these values were analyzed separately as men and women, they were found to be 2.6 ± 2.02 , 41.8 ± 1.23 and 134 ± 2.8 in women and 1.99 ± 1.03 , 19.8 ± 75.6 and 24.5 ± 1.32 in men. There was a significant difference between men and women in terms of Anti-TG and

Anti-TPO values ($p=0.011$ and $p=0.001$, respectively).

Mann-Whitney U test showed no significant association between nail involvement and TSH, Anti-TG and Anti-TPO ($p=0.65$, $p=0.49$ and $p=0.38$, respectively). No significant association was observed between comorbidities and TSH and Anti-TG ($p=0.172$ and $p=0.226$, respectively). However, there was a statistically significant relationship between comorbidities and Anti-TPO ($p=0.016$). No significant correlation was observed between the presence of family history and TSH, Anti-TG and anti-TPO ($p=0.68$, $p=0.60$ and $p=0.22$, respectively). Thirty-one (20.4%) patients had psychiatric illness, while 121 (79.6%) did not. No significant correlation was observed between the presence of psychiatric disease and TSH, Anti-TG and Anti-TPO ($p=0.78$, $p=0.59$ and $p=0.17$, respectively) (Table 1).

There was no significant correlation between age and disease duration and Anti-TG, Anti-TPO ($p=0.069$, $p=0.633$ and $p=0.205$, respectively) (Spearman's correlation test).

A significant correlation was found between disease duration and Anti-TPO positivity ($p=0.045$); however, a similar relationship was not found between disease duration and Anti-TG positivity ($p=0.34$) (Table 2).




Figure 1. Patient frequency according to age

Table 1. Comparison of TSH, Anti-TG and Anti TPO with Nail Involvement, Comorbidity, Psychiatric Disease and Family History

			TSH	<i>p</i>	Anti-TG	<i>p</i>	Anti-TPO	<i>p</i>
Nail Involvement	Yes	Mean±SD	2.3±1.21	0.650	63.7±1.98	0.490	67.7±2.13	0.380
	No	Mean±SD	2.28±1.60		26.2±86		116±2.94	
Comorbidity	Yes	Mean±SD	2.78±2.18	0.172	62.2±1.5	0.226	178±3.31	0.016
	No	Mean±SD	2.02±1.06		12.5±48.9		17.3±97.7	
Psychiatric Disease	Yes	Mean±SD	2.32±1.44	0.780	86.3±184	0.590	67±222	0.170
	No	Mean±SD	2.27±1.6		29.9±86.1		102.2±227	
Family History	Yes	Mean±SD	2.09±1.3	0.680	18.5±47.9	0.600	132±276.9	0.220
	No	Mean±SD	2.31±1.6		47.3±125.8		66.2±215	

TSH: Thyroid-stimulating hormone; Anti-TG: Anti-Thyroglobulin antibody; Anti-TPO: Anti-Thyroid peroxidase antibody

Table 2. The Relationship Between Anti-TPO and Anti-TG and Disease Duration (Median)

	Anti-TPO		Anti-TG	
	Positive	Negative	Positive	Negative
Disease duration (days) (median)	365	90	272	90

Anti-TG: Anti-Thyroglobulin antibody; Anti-TPO: Anti-Thyroid peroxidase antibody

DISCUSSION

Alopecia areata is a disease that occurs at a young age, most commonly between the 2nd and 4th decades, with a prevalence reported to be 0.1%. Finner et al. reported that 66% of the patients were under the age of 30 years and the disease was very rare under the age of 3 years.¹¹ In a study performed in Iran, 69.9% of the patients were seen in the first two decades and the mean age was 24.05±9.98 years.¹⁰ In studies conducted in Turkey, the age of disease was found to be 32.4±8.32, 25.87±12.57, 26.72±12.91.¹²⁻¹⁴ In our study, the age range of the patients was 2-64 years and the mean age was 26.5±14.6 years. The mean age was 27.5±14.4 years in women and 25.7±14.9 years in men. There were only three patients under the age of three years. The majority of the patients between the ages of 25-30 years constituted the largest age group with a rate of 21.7%. 68.4% of the patients were under 30 years of age and 21% were over 40 years of age. These findings were found to be consistent with the literature.

In a study conducted in Greece in which 637 patients participated, it was reported that male patients were more common, which was compatible with the data of studies in France, Italy and Spain.¹⁵ The study data in Turkey are mixed, and in addition to the publications with a higher proportion of women (52.7% of the patients were women and 47.3% were men in the study by Kılınc et al.), 2 separate studies, one of which was multicenter (38.2% of the patients were women

and 61.8% were men in the study by Kavak et al.), reported a higher proportion of men.¹⁶⁻¹⁸ Contrary to the literature, AA was found to be higher in men in our study. However, this is a cosmetic problem and may be more common in women because they are more concerned about their appearance. As our study did not include patients without thyroid autoantibodies, the sex distribution may be different for all AA patients, and this may explain why our study found AA predominantly in men.

In terms of the type and pattern of involvement of AA, Polat et al. reported 90.2% of cases as AA, 5.5% as AU and 4.1% as AT. In the same study, 75.3% scalp, 20% beard, 0.77% scalp and eyebrow, 3.8% eyebrow or eyelash involvement were found.¹³ Kyriakis et al. reported 50.5% beard, 39.3% scalp, 9.2% scalp and beard, and 1% eyebrows in male patients, but no rate was given for female patients.¹⁵ Finner found patch type in 75% of patients with AA and 10-20% AT.¹¹ In the study by Kılınc et al. 63% of the patients were AA, 11% were AT and 36% were AU.¹⁸ In our study, 74.7% of the patients had patch-type involvement, which is consistent with the studies discussed above.

Nail changes in alopecia areata have been found to be 10%, 9%, 20% in various studies.^{11,18} The result in our study was 7.9%, which is lower than the literature. The fact that the study was retrospective and nail changes developed later may be a factor in this.

Lutz et al. found diffuse goiter in 70% and nodular goiter in 12% of 120 patients with AA aged 7-60 years; 115 (96%) of these patients were euthyroid,

three (2.5%) had subclinical hypothyroidism, two (1.66%) had subclinical hyperthyroidism and one (0.83%) had Hashimoto's thyroiditis.¹⁹ In addition, thyroid dysfunction was found to be 24.4% and 20.2% in 2 separate studies conducted in children under 16 years of age.²⁰ In another study in a group of 80 pediatric patients under 12 years of age, thyroid dysfunction was similarly found to be 17.5%. In the same study, thyroid autoantibody levels were found to be 14%.²¹ In our study, children under 16 years of age constituted 27.6% of the patients with AA and thyroid dysfunction was found in 17.2% and thyroid autoantibody elevation in 13.7%. It was consistent with the literature.

In this study, thyroid autoantibody elevation was found in 19% of all patients and this value was not statistically significant. In addition, the mean TSH value was calculated as 3.58 in this autoantibody elevated group. This value was higher than the TSH value of 2.2 found by Baars et al. in AA patients with thyroid autoantibody positivity; in the same study, the TSH value was 1.6 in the group without thyroid autoantibody positivity.²² In addition, in our study, 35% of women had thyroid autoantibody positivity whereas only 6.8% of men had antibody positivity. This result suggests that autoimmunity is affected by gender in accordance with the literature.^{17,23}

When the family history of patients with alopecia areata was analyzed, family history was found to be 4-42%, 10-20%, 29.6%, 42%.²⁴ Gönül et al. 2011, they found family history to be 15.9%; and found a correlation between the length of disease duration and thyroid otonticor positivity.¹⁷ In our study, family history was present in 17 (11.2%) patients with AA. In addition, among the tests indicating thyroid autoimmunity, only Anti-TPO was significantly associated with the duration of AA. A similar relationship could not be demonstrated with Anti-TG.

In our study, elevated levels of at least one of anti-TG and anti-TPO were found in 29 (19.07%) patients with AA. In this group of patients with elevated autoantibodies, 15 (9.8%) patients were diagnosed with thyroid disease and recorded. We could not find any information about the disease in the remaining 14 patients because they stopped their follow-up. In a study conducted in Iran, a high rate of association was found between impaired thyroid function and elevated serum autoantibody levels in patients with AA. This was explained by the high number of female patients included in the study (-thyroid diseases are more common in the female gender).¹⁰ In our study,

the association with thyroid disease may not have been found to be high due to the high number of male patients. When similar studies were analyzed, the prevalence of thyroid disease was found between 1-20% and 8-28% [10, 24].

The prevalence of vitiligo in AA patients was found to be between 1.5% and 4% in studies.^{11,17,25} In our study, vitiligo was detected in 2 (3.8%) of the participants. No different results were found from other studies.

The effect of stress in patients with alopecia areata has been examined in many studies with different results. Psychopathology was shown to be associated with 17.7% of 132 patients with AA in our country.¹⁷ In Belgium, it was shown that psychological and traumatic events were more frequent in people with AA than in healthy controls.²⁶ In a study conducted in pediatric AA patients, emotional stress was reported to be present in 57% of patients [21]. In our results, we could not show a significant correlation between the presence of psychiatric disease and TSH, Anti-TG and Anti-TPO in patients with AA. We found a significant correlation only between all types of diseases accompanying AA and Anti-TPO, but not with Anti-TG.

The epidemiologic data of our study were similar to those of other studies conducted in our country. The limitations of our study include the inaccessibility of all data since the cases were screened retrospectively, not representing the entire AA population since it was a single-center study in which patients in our outpatient clinic were examined cross-sectionally, and the lack of genetic findings. As a result of this study, although there was a significant correlation between anti-TPO and the duration of AA, the association between thyroid autoimmunity and AA was not statistically significant. In our study, no correlation was found between AA and autoimmune thyroiditis, suggesting that cellular immunity rather than humoral immunity is predominant in the etiology of AA. Again, considering that autoimmune mechanisms are more predominant in female patients compared to male patients and considering that the number of female patients in our study was less than the number of male patients, it can be considered as one of the reasons for the lack of statistical significance between thyroid autoimmunity and AA.^{17,23,27}

CONCLUSION

In our study, patch type AA was found in 98.6% and alopecia totalis in 1.4%. The scalp was involved in 74.7% and the beard in 11.8%. Nail involvement was seen in only 7.9% of patients. Elevated thyroid autoantibodies were found in 19.0%, of whom 10 had hypothyroidism, 2 had chronic thyroiditis and 3 had toxic multinodular goiter. Although there was a significant correlation between anti-TPO and duration of AA, the association between thyroid autoimmunity and AA was not found to be statistically significant. This may be due to the fact that humoral autoimmunity plays a role in thyroid autoimmunity and primarily cellular autoimmunity plays a role in AA. In addition, the epidemiologic data of our study were similar to the data of studies conducted in our country

Conflict of Interest

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding Sources

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethical Approval

The protocol of the study was approved by the Medical Ethics Committee of Trakya University Faculty of Medicine, Edirne, Turkey. (Decision number: 3-15, date: 11.01.2012).

Authors' Contribution

Study Conception: HNS, AG; Study Design: HNS, AG; Supervision: HNS, AG; Funding: HNS, AG; Materials: HNS; Data Collection and/or Processing: HNS; Analysis and/or Data Interpretation: HNS, AG; Literature Review: HNS, AG; Critical Review: HNS, AG; Manuscript preparing: HNS, AG.

REFERENCES

1. Sterkens A, Lambert J, Bervoets A. Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options. *Clin Exp Med*. 2021 May;21(2):215-230. doi: 10.1007/s10238-020-00673-w.
2. Griffiths, C. E., Barker, J., Bleiker, T. O., Chalmers, R., & Creamer, D. (Eds.). (2016). *Rook's textbook of dermatology*. John Wiley & Sons.
3. Parish, L. C. (2011). Andrews' diseases of the skin: clinical dermatology. *JAMA*, 306(2), 213-213.
4. Fukuyama M, Ito T, Ohyama M. Alopecia areata: Current understanding of the pathophysiology and update on therapeutic approaches, featuring the Japanese Dermatological Association guidelines. *J Dermatol*. 2022 Jan;49(1):19-36. doi: 10.1111/1346-8138.16207. Epub 2021 Oct 28.
5. McMichael AJ, Roberson ML. Characterizing Epidemiology and Burden of Disease in Alopecia Areata-Making It Count. *JAMA Dermatol*. 2023 Apr 1;159(4):369-370. doi: 10.1001/jamadermatol.2023.0001.
6. Zhou C, Li X, Wang C, Zhang J. Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management. *Clin Rev Allergy Immunol*. 2021 Dec;61(3):403-423. doi: 10.1007/s12016-021-08883-0.
7. Melikoglu M, Sahin M, Alkan Melikoglu M. Vitamin D in Behcet's Disease, a Brief Review of the Literature. *Eurasian J Med*. 2022 Dec;54(Suppl1):29-33. doi: 10.5152/eurasianjmed.2022.22300.
8. Athanassiou L, Kostoglou-Athanassiou I, Koutsilieris M, Shoenfeld Y. Vitamin D and Autoimmune Rheumatic Diseases. *Biomolecules*. 2023 Apr 21;13(4):709. doi: 10.3390/biom13040709.
9. Ly S, Manjaly P, Kamal K, Shields A, Wafae B, Afzal N, Drake L, Sanchez K, Gregoire S, Zhou G, Mita C, Mostaghimi A. Comorbid Conditions Associated with Alopecia Areata: A Systematic Review and Meta-analysis. *Am J Clin Dermatol*. 2023 Nov;24(6):875-893. doi: 10.1007/s40257-023-00805-4.
10. Seyrafi H, Akhiani M, Abbasi H, Mirpour S, Gholamrezanezhad A. Evaluation of the profile of alopecia areata and the prevalence of thyroid function test abnormalities and serum autoantibodies in Iranian patients. *BMC Dermatol*. 2005 Oct 31;5:11. doi: 10.1186/1471-5945-5-11.
11. Finner AM. Alopecia areata: Clinical presentation, diagnosis, and unusual cases. *Dermatol Ther*. 2011 May-Jun;24(3):348-54. doi: 10.1111/j.1529-8019.2011.01413.x.
12. Naik PP, Farrukh SN. Association between alopecia areata and thyroid dysfunction. *Postgrad Med*. 2021 Nov;133(8):895-898. doi: 10.1080/00325481.2021.1974689. Epub 2021 Sep 6.

13. Polat, M., A.H. Parlak, and B. Şereflican, Dermatoloji kliniğinde görülen alopesi areatalı hastaların klinik ve epidemiyolojik özellikleri. *Göztepe Tıp Dergisi*, 2010. 25(2): p. 86-90.
14. Hayran Y, Gunindi Korkut M, Öktem A, Şen O, Gür Aksoy G, Özmen F. Evaluation of HLA class I and HLA class II allele profile and its relationship with clinical features in patients with alopecia areata: a case-control study. *J Dermatolog Treat*. 2022 Jun;33(4):2175-2181. doi: 10.1080/09546634.2021.1937478. Epub 2021 Jun 21.
15. Kyriakis KP, Paltatzidou K, Kosma E, Sofouri E, Tadros A, Rachioti E. Alopecia areata prevalence by gender and age. *J Eur Acad Dermatol Venereol*. 2009 May;23(5):572-3. doi: 10.1111/j.1468-3083.2008.02956.x. Epub 2008 Sep 3.
16. Kavak A, Baykal C, Ozarmağan G, Akar U. HLA in alopecia areata. *Int J Dermatol*. 2000 Aug;39(8):589-92. doi: 10.1046/j.1365-4362.2000.00921.x.
17. Gönül, M., Gül, Ü., Piskin, E., Çakmak, S. K., Soylu, S., Kiliç, A., & Biyikli, Z. (2011). Alopesi Areatalı Hastaların Geriye Dönük Değerlendirilmesi/Retrospective Evaluation of Alopecia Areata Patients. *Turk Dermatoloji Dergisi*, 5(2), 43.
18. Kılınç, İ., Alper, S., Ceylan, C., & İdil, Ü. N. A. L. (2002). Alopesi Areatalı olgularda hasta profili: Bir retrospektif çalışma. *Ege Tıp Dergisi*, 41(1), 25-27.
19. Lutz, G., Biersack, H. J., Bauer, R., & Kreysel, H. W. (1987). Value of pathologic thyroid gland findings in alopecia areata. *Zeitschrift für Hautkrankheiten*, 62(17), 1253-1261.
20. Tosti A, Bellavista S, Iorizzo M. Alopecia areata: a long term follow-up study of 191 patients. *J Am Acad Dermatol*. 2006 Sep;55(3):438-41. doi: 10.1016/j.jaad.2006.05.008. Epub 2006 Jun 27.
21. Nanda A, Al-Fouzan AS, Al-Hasawi F. Alopecia areata in children: a clinical profile. *Pediatr Dermatol*. 2002 Nov-Dec;19(6):482-5. doi: 10.1046/j.1525-1470.2002.00215.x.
22. Baars MP, Greebe RJ, Pop VJ. High prevalence of thyroid peroxidase antibodies in patients with alopecia areata. *J Eur Acad Dermatol Venereol*. 2013 Jan;27(1):e137-9. doi: 10.1111/j.1468-3083.2011.04420.x. Epub 2012 Jan 6.
23. Goh, C., et al., Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. *J Eur Acad Dermatol Venereol*, 2006. 20(9): p. 1055-60.
24. Özden, M.G., et al., Çocukluk Çağı Alopesi Areata Hastalarının Klinik Özellikleri ve Seyri. *Turkish Journal of Dermatology/Turk Dermatoloji Dergisi*, 2010. 4(3).
25. Green, J. and R.D. Sinclair, Genetics of alopecia areata. *Australas J Dermatol*, 2000. 41(4): p. 213-8.
26. Willemsen, R., et al., Increased history of childhood and lifetime traumatic events among adults with alopecia areata. *J Am Acad Dermatol*, 2009. 60(3): p. 388-93.
27. Fairweather, D., S. Frisancho-Kiss, and N.R. Rose, Sex differences in autoimmune disease from a pathological perspective. *Am J Pathol*, 2008. 173(3): p. 600-9.

A case of recurrent acute pancreatitis following ocrelizumab therapy

Elif Işıklar¹, Berivan Akdoğan¹, Uygur Yavaş¹, İsmail Demir¹

Internal Medicine, University Of Health Sciences Bozyaka Training And Research Hospital, İzmir, Türkiye

ABSTRACT

Acute pancreatitis is an acute inflammatory process of the pancreas. Drugs are a relatively rare cause of acute pancreatitis with an incidence of 0.1-2%. Ocrelizumab is a monoclonal antibody that causes peripheral B lymphocyte suppression by targeting CD20 receptors on B lymphocytes. In this case report, we aimed to present a case of acute pancreatitis after ocrelizumab use. It is thought that suppression of B lymphocytes by ocrelizumab may induce proinflammatory cytokine release and may also cause pancreatitis by disrupting T lymphocyte regulation. Therefore, ocrelizumab should be considered in the etiology of pancreatitis in patients receiving ocrelizumab treatment.

Keywords: Ocrelizumab, Pancreatitis

Acute pancreatitis is an acute, inflammatory process of the pancreas. Acute pancreatitis presents with typical epigastric pain, high lipase and amylase levels (above 3 times upper limit of normal) and imaging findings. The diagnosis of acute pancreatitis is made by the presence of two of these three findings.¹ Gallstones (40%-70%), alcohol (25%-35%), hyperlipidemia and drugs are the most common etiology of pancreatitis, respectively. With an incidence of 0.1-2%, drugs are a relatively rare cause of acute pancreatitis.² The drugs with the highest epidemiological risk are mesalazine, azathioprine and simvastatin. Drug-associated pancreatitis has a good prognosis and low mortality rate.³

Ocrelizumab is a monoclonal antibody that causes the suppression of peripheral B lymphocytes by targeting the CD20 receptors on the B lymphocytes.⁴ It is used in cases of relapsing refractory multiple sclerosis, or progressive multiple sclerosis. Common side effects include skin infections, decrease in neutrophil and im-

munoglobulin levels, hypersensitivity reactions and infections. Diarrhea has been reported as a gastrointestinal adverse event with a rate of 6%. With a frequency of 0.2%, pancreatitis following ocrelizumab use is a serious adverse event.

In this case report, we aimed to present a case that we followed up with the diagnosis of pancreatitis attack after ocrelizumab use.

CASE REPORT

A 53-year-old woman with a history of hypothyroidism and relapsing refractory multiple sclerosis (MS) was presented to our clinic for her fourth episode of acute pancreatitis. The patient was diagnosed with MS in 1997 and was on betaferon and azacitidine for 6 years after diagnosis. The patient was then followed up with alternating cyclophosphamide and pulse steroid and baclofen treatment every 2 months. In April 2021,

Received: August 20, 2023; *Accepted:* April 23, 2024; *Published Online:* April 29, 2024

How to cite this article: Işıklar E, Akdoğan B, Yavaş U, Demir İ. A case of recurrent acute pancreatitis following ocrelizumab use. DAHUDER MJ 2024,4(2):61-63. DOI: 10.56016/dahudermj.1267120

Address for correspondence: Elif Işıklar, Bozyaka Eğitim ve Araştırma Hastanesi, Karabağlar, İzmir, Türkiye
E-mail: elifalapala@gmail.com

Available at <http://dergipark.org.tr/en/pub/dahudermj>




Figure 1. Increased pancreatic volume with impurity in the head and corpus.

the patient was made ready to receive ocrelizumab, and the first full dose of ocrelizumab was administered in June 2021. Four months after the first dose, amylase: 3262 U/L, lipase: 2853 U/L, calcium: 9.2 mg/dl, triglyceride: 90 mg/dl were observed when the patient presented to the emergency department with abdominal pain in November 2021. No additional pathology was found in his hemogram and biochemistry tests. Her abdominal tomography scan was reported to be compatible with edematous pancreatitis (Figure 1). Her extrahepatic bile ducts were assessed as being normal and no dilatation was found. The patient was referred with the diagnosis of acute pancreatitis. When the anamnesis of the patient who received three full doses of ocrelizumab treatment was deepened, it was observed that the pancreatitis attacks occurred approximately one to four months after the ocrelizumab doses had been received. When the retrospective hospital records of the patient with no history of alcohol consumption were examined, hypercalcemia, hyperlipidemia and cholecystopathy were not found in the etiology of the four pancreatitis attacks. In the patient examined for autoimmune pancreatitis, IG-G4 levels were normal and no etiological cause of pancreatitis was found. When the patient's treatment history was analyzed in detail, it was observed that pancreatitis attacks started after ocrelizumab treatment. Considering ocrelizumab in the etiology of pancreatitis, the patient was evaluated in collaboration with the neurology department and the literature was reviewed for the adverse event profile of the drug. As ocrelizumab was considered in the etiology of pancreatitis, ocrelizumab treatment was discontinued and the MS management was reorganized.

DISCUSSION

Possibly due to under-diagnosis, drug-associated pancreatitis is a rare disease entity.⁵ Immunological reactions, direct toxic effects, accumulation of toxic metabolites, ischemia, intravascular thrombosis and the increase in viscosity of pancreatic juice are mechanisms of drug-induced pancreatitis.⁶ While most drugs cause pancreatitis in the first few weeks of use, this period can last for months or even years.⁷ Though the exact mechanism by which ocrelizumab causes pancreatitis is unknown, B-lymphocyte suppression has been shown to induce proinflammatory cytokine release in a model of inflammatory bowel disease.⁸ Meanwhile, B lymphocyte suppression disrupts T lymphocyte regulation and may lead to inflammatory changes.

CONCLUSION

By stimulating the inflammatory process, ocrelizumab treatment may be involved in the etiology of pancreatitis. Therefore, ocrelizumab should be considered in the etiology of pancreatitis in patients receiving ocrelizumab treatment.

Conflict of Interest

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Authors' Contribution

Study Conception: EI, BA, UY, ID; Study Design:

EI, BA, UY, İD; Supervision; EI, BA, UY, İD; Funding: İD, EI; Materials: İD, EI; Data Collection and/or Processing: İD, EI; Analysis and/or Data Interpretation: EI; Literature Review: EI; Critical Review: EI, BA, UY; Manuscript preparing: EI.

REFERENCES

1. Szatmary P, Grammatikopoulos T, Cai W, Huang W, Mukherjee R, Halloran C, Beyer G, Sutton R. Acute Pancreatitis: Diagnosis and Treatment. *Drugs*. 2022 Aug;82(12):1251-1276. doi: 10.1007/s40265-022-01766-4.
2. Balani AR, Grendell JH. Drug-induced pancreatitis: incidence, management and prevention. *Drug Saf*. 2008;31(10):823-37. doi: 10.2165/00002018-200831100-00002.
3. Simons-Linares CR, Elkhoully MA, Salazar MJ. Drug-Induced Acute Pancreatitis in Adults: An Update. *Pancreas*. 2019 Nov/Dec;48(10):1263-1273. doi: 10.1097/MPA.0000000000001428.
4. Juanatey A, Blanco-Garcia L, Tellez N. Ocrelizumab: its efficacy and safety in multiple sclerosis. *Rev Neurol*. 2018 Jun 16;66(12):423-433.
5. Spanier BW, Tuynman HA, van der Hulst RW, Dijkgraaf MG, Bruno MJ. Acute pancreatitis and concomitant use of pancreatitis-associated drugs. *Am J Gastroenterol*. 2011 Dec;106(12):2183-8. doi: 10.1038/ajg.2011.303.
6. Sadr-Azodi O, Mattsson F, Bexlius TS, Lindblad M, Lagergren J, Ljung R. Association of oral glucocorticoid use with an increased risk of acute pancreatitis: a population-based nested case-control study. *JAMA Intern Med*. 2013 Mar 25;173(6):444-9. doi: 10.1001/jamainternmed.2013.2737.
7. Badalov N, Baradaran R, Iswara K, Li J, Steinberg W, Tenner S. Drug-induced acute pancreatitis: an evidence-based review. *Clin Gastroenterol Hepatol*. 2007 Jun;5(6):648-61; quiz 644. doi: 10.1016/j.cgh.2006.11.023.
8. Mizoguchi E, Mizoguchi A, Preffer FI, Bhan AK. Regulatory role of mature B cells in a murine model of inflammatory bowel disease. *Int Immunol*. 2000 May;12(5):597-605. doi: 10.1093/intimm/12.5.597.



This is an open access article distributed under the terms of [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License](https://creativecommons.org/licenses/by-nc-nd/4.0/).